<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bull World Health Organ</journal-id><journal-id journal-id-type="iso-abbrev">Bull. World Health Organ</journal-id><journal-id journal-id-type="publisher-id">BLT</journal-id><journal-title-group><journal-title>Bulletin of the World Health Organization</journal-title></journal-title-group><issn pub-type="ppub">0042-9686</issn><issn pub-type="epub">1564-0604</issn><publisher><publisher-name>World Health Organization</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30104797</article-id><article-id pub-id-type="pmc">6083393</article-id><article-id pub-id-type="publisher-id">BLT.18.207944</article-id><article-id pub-id-type="doi">10.2471/BLT.18.207944</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Cost&#x02013;effectiveness of risk-based breast cancer screening programme, China</article-title><trans-title-group xml:lang="fr"><trans-title xml:lang="fr">Rapport co&#x000fb;t-efficacit&#x000e9; du programme de d&#x000e9;pistage du cancer du sein fond&#x000e9; sur les risques en Chine</trans-title></trans-title-group><trans-title-group xml:lang="es"><trans-title xml:lang="es">Rentabilidad del programa de detecci&#x000f3;n del c&#x000e1;ncer de mama basado en el riesgo en China</trans-title></trans-title-group><trans-title-group xml:lang="ar"><trans-title xml:lang="ar">&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00641;&#x0062d;&#x00635; &#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00627;&#x00644;&#x00642;&#x00627;&#x00626;&#x00645; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x0062e;&#x00627;&#x00637;&#x00631;&#x0060c; &#x00627;&#x00644;&#x00635;&#x0064a;&#x00646; </trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title xml:lang="zh">&#x04e2d;&#x056fd;&#x057fa;&#x04e8e;&#x098ce;&#x09669;&#x07684;&#x04e73;&#x0817a;&#x0764c;&#x07b5b;&#x067e5;&#x09879;&#x076ee;&#x07684;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x05206;&#x06790;</trans-title></trans-title-group><trans-title-group xml:lang="ru"><trans-title xml:lang="ru">&#x0042d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00430;&#x0044f; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x00436;&#x00435;&#x0043b;&#x00435;&#x00437;&#x0044b; &#x0043d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00435; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00430;, &#x0041a;&#x00438;&#x00442;&#x00430;&#x00439;</trans-title></trans-title-group><alt-title alt-title-type="author-running-head">Li Sun et al.</alt-title><alt-title alt-title-type="title-running-head">Breast cancer screening, China</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Legood</surname><given-names>Rosa</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sadique</surname><given-names>Zia</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>dos-Santos-Silva</surname><given-names>Isabel</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><aff id="aff1"><label>a</label>Department of Health Services Research and Policy, <institution>London School of Hygiene and Tropical Medicine</institution>, <addr-line>London</addr-line>, <country>England</country>.</aff><aff id="aff2"><label>b</label>Department of Noncommunicable Disease Epidemiology, <institution>London School of Hygiene and Tropical Medicine</institution>, <addr-line>London</addr-line>, <country>England</country>.</aff><aff id="aff3"><label>c</label>School of Public Health, Peking University, NO.38 Xueyuan Road, Haidian District, <addr-line>Beijing 100191</addr-line>, <country>China</country>.</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to Li Yang (email: <email xlink:href="lyang@bjmu.edu.cn">lyang@bjmu.edu.cn</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>8</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2018</year></pub-date><volume>96</volume><issue>8</issue><fpage>568</fpage><lpage>577</lpage><history><date date-type="received"><day>03</day><month>1</month><year>2018</year></date><date date-type="rev-recd"><day>14</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2018</year></date></history><permissions><copyright-statement>(c) 2018 The authors; licensee World Health Organization.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/igo/legalcode">http://creativecommons.org/licenses/by/3.0/igo/legalcode</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any reproduction of this article there should not be any suggestion that WHO or this article endorse any specific organization or products. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.</license-p></license></permissions><abstract><title>Abstract</title><sec><title>Objective</title><p>To model the cost&#x02013;effectiveness of a risk-based breast cancer screening programme in urban China, launched in 2012, compared with no screening.</p></sec><sec><title>Methods</title><p>We developed a Markov model to estimate the lifetime costs and effects, in terms of quality-adjusted life years (QALYs), of a breast cancer screening programme for high-risk women aged 40&#x02013;69&#x000a0;years. We derived or adopted age-specific incidence and transition probability data, assuming a natural history progression between the stages of cancer, from other studies. We obtained lifetime direct and indirect treatment costs in 2014 United States dollars (US$) from surveys of breast cancer patients in 37 Chinese hospitals. To calculate QALYs, we derived utility scores from cross-sectional patient surveys. We evaluated incremental cost&#x02013;effectiveness ratios for various scenarios for comparison with a willingness-to-pay threshold.</p></sec><sec><title>Findings</title><p>Our baseline model of annual screening yielded an incremental cost&#x02013;effectiveness ratio of US$&#x000a0;8253/QALY, lower than the willingness-to-pay threshold of US$&#x000a0;23&#x02009;050/QALY. One-way and probabilistic sensitivity analyses demonstrated that the results are robust. In the exploration of various scenarios, screening every 3&#x000a0;years is the most cost&#x02013;effective with an incremental cost&#x02013;effectiveness ratio of US$&#x000a0;6671/QALY. The cost&#x02013;effectiveness of the screening is reduced if not all diagnosed women seek treatment. Finally, the economic benefit of screening women aged 45&#x02013;69&#x000a0;years with both ultrasound and mammography, compared with mammography alone, is uncertain.</p></sec><sec><title>Conclusion</title><p>High-risk population-based breast cancer screening is cost&#x02013;effective compared with no screening.</p></sec></abstract><trans-abstract xml:lang="fr"><title>R&#x000e9;sum&#x000e9; </title><sec><title>Objectif</title><p>Mod&#x000e9;liser le rapport co&#x000fb;t-efficacit&#x000e9; d'un programme de d&#x000e9;pistage du cancer du sein fond&#x000e9; sur les risques en Chine urbaine, lanc&#x000e9; en&#x000a0;2012, compar&#x000e9; &#x000e0; l'absence de d&#x000e9;pistage.</p></sec><sec><title>M&#x000e9;thodes</title><p>Nous avons &#x000e9;labor&#x000e9; un mod&#x000e8;le de Markov pour estimer le co&#x000fb;t et les effets portant sur la vie enti&#x000e8;re, au regard des ann&#x000e9;es de vie pond&#x000e9;r&#x000e9;es par la qualit&#x000e9; (QALY), d'un programme de d&#x000e9;pistage du cancer du sein chez les femmes &#x000e0; haut risque &#x000e2;g&#x000e9;es de 40&#x000a0;&#x000e0;&#x000a0;69&#x000a0;ans. Nous avons tir&#x000e9; ou adopt&#x000e9; des donn&#x000e9;es sur l'incidence selon l'&#x000e2;ge et la probabilit&#x000e9; de transition, dans l'hypoth&#x000e8;se d'une &#x000e9;volution naturelle entre les phases du cancer, &#x000e0; partir d'autres &#x000e9;tudes. Nous avons obtenu les co&#x000fb;ts directs et indirects de traitement au cours d'une vie en dollars des &#x000c9;tats-Unis de&#x000a0;2014 ($US) &#x000e0; partir d'enqu&#x000ea;tes men&#x000e9;es aupr&#x000e8;s de patientes atteintes du cancer du sein dans 37&#x000a0;h&#x000f4;pitaux chinois. Pour calculer les QALY, nous avons d&#x000e9;duit des scores d'utilit&#x000e9; &#x000e0; partir d'enqu&#x000ea;tes transversales aupr&#x000e8;s de patientes. Nous avons &#x000e9;valu&#x000e9; le rapport co&#x000fb;t-efficacit&#x000e9; diff&#x000e9;rentiel selon diff&#x000e9;rents sc&#x000e9;narios pour &#x000e9;tablir une comparaison avec un seuil de consentement &#x000e0; payer.</p></sec><sec><title>R&#x000e9;sultats</title><p>Notre mod&#x000e8;le de r&#x000e9;f&#x000e9;rence de d&#x000e9;pistage annuel a donn&#x000e9; un rapport co&#x000fb;t-efficacit&#x000e9; diff&#x000e9;rentiel de 8253&#x000a0;$US/QALY, soit moins que le seuil de consentement &#x000e0; payer de 23&#x000a0;050&#x000a0;$US/QALY. Les analyses &#x000e0; un seul crit&#x000e8;re de classification et de sensibilit&#x000e9; probabiliste ont d&#x000e9;montr&#x000e9; que les r&#x000e9;sultats sont fiables. L'examen de diff&#x000e9;rents sc&#x000e9;narios a r&#x000e9;v&#x000e9;l&#x000e9; que le d&#x000e9;pistage tous les 3&#x000a0;ans pr&#x000e9;sente le meilleur rapport co&#x000fb;t-efficacit&#x000e9;, avec un rapport co&#x000fb;t-efficacit&#x000e9; diff&#x000e9;rentiel de 6671&#x000a0;$US/QALY. Le rapport co&#x000fb;t-efficacit&#x000e9; du d&#x000e9;pistage est r&#x000e9;duit si toutes les femmes diagnostiqu&#x000e9;es ne se font pas soigner. Enfin, l'avantage &#x000e9;conomique li&#x000e9; au d&#x000e9;pistage des femmes &#x000e2;g&#x000e9;es de 45&#x000a0;&#x000e0; 69&#x000a0;ans par &#x000e9;chographie et mammographie, compar&#x000e9; &#x000e0; un d&#x000e9;pistage par mammographie uniquement, est incertain.</p></sec><sec><title>Conclusion</title><p>Le d&#x000e9;pistage du cancer du sein dans les populations &#x000e0; haut risque pr&#x000e9;sente un bon rapport co&#x000fb;t-efficacit&#x000e9; par rapport &#x000e0; l'absence de d&#x000e9;pistage.<bold/></p></sec></trans-abstract><trans-abstract xml:lang="es"><title>Resumen</title><sec><title>Objetivo</title><p>Demostrar la rentabilidad de un programa de detecci&#x000f3;n del c&#x000e1;ncer de mama basado en el riesgo en las zonas urbanas de China, iniciado en 2012, en comparaci&#x000f3;n con la ausencia de detecci&#x000f3;n.</p></sec><sec><title>M&#x000e9;todos</title><p>Se desarroll&#x000f3; un modelo Markov para estimar los costes y efectos durante el ciclo vital, en t&#x000e9;rminos de a&#x000f1;os de vida ajustados por calidad de vida (AVAC), de un programa de detecci&#x000f3;n del c&#x000e1;ncer de mama para mujeres con alto riesgo de entre 40 y 69 a&#x000f1;os de edad. Se obtuvieron o adoptaron datos de la probabilidad de incidencia y transici&#x000f3;n espec&#x000ed;ficos por edad, sobre la hip&#x000f3;tesis de una progresi&#x000f3;n de la historia natural entre los estadios del c&#x000e1;ncer, a partir de otros estudios. Se obtuvieron los costes directos e indirectos del tratamiento vitalicio en d&#x000f3;lares estadounidenses (USD) en 2014 a partir de encuestas a pacientes con c&#x000e1;ncer de mama en 37 hospitales de China. Para calcular los AVAC, se derivaron las puntuaciones de los servicios p&#x000fa;blicos de las encuestas transversales a los pacientes. Se evaluaron las relaciones de rentabilidad incrementales para diversos escenarios en comparaci&#x000f3;n con un umbral de la disposici&#x000f3;n a pagar.</p><sec><title>&#x0200b;</title><p>Resultados Nuestro modelo de referencia de detecci&#x000f3;n anual revel&#x000f3; una relaci&#x000f3;n de rentabilidad incremental de 8253 USD/AVAC, por debajo del umbral de disposici&#x000f3;n a pagar de 23&#x000a0;050 USD/AVAC. Los an&#x000e1;lisis de sensibilidad unidireccionales y de probabilidad demostraron que los resultados son s&#x000f3;lidos. En la exploraci&#x000f3;n de varios escenarios, la detecci&#x000f3;n cada 3 a&#x000f1;os es la m&#x000e1;s rentable, con una relaci&#x000f3;n de rentabilidad incremental de 6671 USD/AVAC. La rentabilidad de la detecci&#x000f3;n se reduce si no todas las mujeres diagnosticadas buscan tratamiento. Finalmente, el beneficio econ&#x000f3;mico de la detecci&#x000f3;n en mujeres de 45 a 69 a&#x000f1;os de edad con ultrasonido y mamograf&#x000ed;a, en comparaci&#x000f3;n con solo la mamograf&#x000ed;a, es incierto.</p></sec></sec><sec><title>Conclusi&#x000f3;n</title><p>La detecci&#x000f3;n del c&#x000e1;ncer de mama basada en la poblaci&#x000f3;n de alto riesgo es rentable en comparaci&#x000f3;n con la ausencia de detecci&#x000f3;n.</p></sec></trans-abstract><trans-abstract xml:lang="ar"><title>&#x00645;&#x00644;&#x0062e;&#x00635; </title><sec><title>&#x00627;&#x00644;&#x0063a;&#x00631;&#x00636; </title><p>&#x00648;&#x00636;&#x00639; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00644;&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00641;&#x0062d;&#x00635; &#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00627;&#x00644;&#x00642;&#x00627;&#x00626;&#x00645; &#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00645;&#x0062e;&#x00627;&#x00637;&#x00631; &#x00641;&#x0064a; &#x00627;&#x00644;&#x00635;&#x0064a;&#x00646; &#x00627;&#x00644;&#x0062d;&#x00636;&#x00631;&#x0064a;&#x00629;&#x0060c; &#x00648;&#x00627;&#x00644;&#x00630;&#x0064a; &#x0062a;&#x00645; &#x00625;&#x00637;&#x00644;&#x00627;&#x00642;&#x00647; &#x00641;&#x0064a; &#x00639;&#x00627;&#x00645; 2012&#x0060c; &#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00628;&#x00639;&#x0062f;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00641;&#x0062d;&#x00635;. </p></sec><sec><title>&#x00627;&#x00644;&#x00637;&#x00631;&#x0064a;&#x00642;&#x00629; </title><p>&#x00644;&#x00642;&#x0062f; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00637;&#x00648;&#x0064a;&#x00631; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c; &#x00645;&#x00627;&#x00631;&#x00643;&#x00648;&#x00641; &#x00644;&#x0062a;&#x00642;&#x0062f;&#x0064a;&#x00631; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00648;&#x00627;&#x00644;&#x00622;&#x0062b;&#x00627;&#x00631; &#x00645;&#x0062f;&#x00649; &#x00627;&#x00644;&#x0062d;&#x0064a;&#x00627;&#x00629;&#x0060c; &#x00628;&#x00627;&#x00644;&#x00646;&#x00633;&#x00628;&#x00629; &#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00639;&#x00645;&#x00631; &#x00645;&#x00639;&#x0062f;&#x00644;&#x00629; &#x00627;&#x00644;&#x0062c;&#x00648;&#x0062f;&#x00629; (QALYs)&#x0060c; &#x00644;&#x00628;&#x00631;&#x00646;&#x00627;&#x00645;&#x0062c; &#x00641;&#x0062d;&#x00635; &#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00644;&#x00644;&#x00646;&#x00633;&#x00627;&#x00621; &#x00627;&#x00644;&#x00645;&#x00639;&#x00631;&#x00636;&#x00627;&#x0062a; &#x00644;&#x0062e;&#x00637;&#x00631; &#x00643;&#x00628;&#x0064a;&#x00631; &#x00641;&#x0064a; &#x00633;&#x00646; &#x00645;&#x00646; 40 &#x00625;&#x00644;&#x00649; 69 &#x00639;&#x00627;&#x00645;&#x00627;&#x0064b;. &#x00644;&#x00642;&#x0062f; &#x00627;&#x00633;&#x0062a;&#x00646;&#x00628;&#x00637;&#x00646;&#x00627; &#x00623;&#x00648; &#x00627;&#x00646;&#x0062a;&#x00647;&#x0062c;&#x00646;&#x00627; &#x00628;&#x0064a;&#x00627;&#x00646;&#x00627;&#x0062a; <styled-content style-type="direction" style="direction:ltr;">-&#x0062a;&#x00639;&#x0062a;&#x00645;&#x0062f; </styled-content>&#x00639;&#x00644;&#x00649; &#x00627;&#x00644;&#x00633;&#x00646;- &#x00644;&#x00627;&#x0062d;&#x0062a;&#x00645;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x00646;&#x0062a;&#x00642;&#x00627;&#x00644; &#x00648;&#x00627;&#x00644;&#x0062d;&#x0062f;&#x00648;&#x0062b;&#x0060c; &#x00628;&#x00627;&#x00641;&#x0062a;&#x00631;&#x00627;&#x00636; &#x0062a;&#x00642;&#x0062f;&#x00645; &#x00627;&#x00644;&#x0062a;&#x00627;&#x00631;&#x0064a;&#x0062e; &#x00627;&#x00644;&#x00637;&#x00628;&#x0064a;&#x00639;&#x0064a; &#x00628;&#x0064a;&#x00646; &#x00645;&#x00631;&#x00627;&#x0062d;&#x00644; &#x00627;&#x00644;&#x00633;&#x00631;&#x00637;&#x00627;&#x00646;&#x0060c; &#x00645;&#x00646; &#x0062f;&#x00631;&#x00627;&#x00633;&#x00627;&#x0062a; &#x00623;&#x0062e;&#x00631;&#x00649;. &#x00644;&#x00642;&#x0062f; &#x0062d;&#x00635;&#x00644;&#x00646;&#x00627; &#x00639;&#x00644;&#x00649; &#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00627;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c; &#x00627;&#x00644;&#x00645;&#x00628;&#x00627;&#x00634;&#x00631; &#x00648;&#x0063a;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00645;&#x00628;&#x00627;&#x00634;&#x00631; &#x00637;&#x00648;&#x00627;&#x00644; &#x00627;&#x00644;&#x00639;&#x00627;&#x00645; 2014 &#x00628;&#x00627;&#x00644;&#x0062f;&#x00648;&#x00644;&#x00627;&#x00631; &#x00627;&#x00644;&#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a; &#x00645;&#x00646; &#x00645;&#x00633;&#x00648;&#x0062d;&#x00627;&#x0062a; &#x00644;&#x00645;&#x00631;&#x0064a;&#x00636;&#x00627;&#x0062a; &#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00641;&#x0064a; 37 &#x00645;&#x00633;&#x0062a;&#x00634;&#x00641;&#x00649; &#x00635;&#x0064a;&#x00646;&#x0064a;&#x0064b;&#x00627;. &#x00644;&#x0062d;&#x00633;&#x00627;&#x00628; QALY&#x0060c; &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; &#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645;&#x00627;&#x0062a; &#x00644;&#x00644;&#x00645;&#x00631;&#x00627;&#x00641;&#x00642; &#x00645;&#x00646; &#x0062e;&#x00644;&#x00627;&#x00644; &#x00645;&#x00633;&#x00648;&#x0062d;&#x00627;&#x0062a; &#x00645;&#x0062a;&#x00639;&#x0062f;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00642;&#x00637;&#x00627;&#x00639;&#x00627;&#x0062a; &#x00644;&#x00644;&#x00645;&#x00631;&#x00636;&#x00649;. &#x00642;&#x00645;&#x00646;&#x00627; &#x00628;&#x0062a;&#x00642;&#x0064a;&#x0064a;&#x00645; &#x00646;&#x00633;&#x00628; &#x00645;&#x0062a;&#x00632;&#x00627;&#x0064a;&#x0062f;&#x00629; &#x00644;&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00627;&#x00644;&#x0064a;&#x00641; &#x00644;&#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00646;&#x00627;&#x00631;&#x0064a;&#x00648;&#x00647;&#x00627;&#x0062a;&#x0060c; &#x00648;&#x00630;&#x00644;&#x00643; &#x00644;&#x00644;&#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00645;&#x00639; &#x00639;&#x0062a;&#x00628;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00644;&#x00644;&#x0062f;&#x00641;&#x00639;. </p></sec><sec><title>&#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; </title><p>&#x00623;&#x00633;&#x00641;&#x00631; &#x00646;&#x00645;&#x00648;&#x00630;&#x0062c;&#x00646;&#x00627; &#x00627;&#x00644;&#x00623;&#x00633;&#x00627;&#x00633;&#x0064a; &#x00644;&#x00644;&#x00641;&#x0062d;&#x00635; &#x00627;&#x00644;&#x00633;&#x00646;&#x00648;&#x0064a; &#x00639;&#x00646; &#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x0062a;&#x00632;&#x00627;&#x0064a;&#x0062f;&#x00629; &#x00644;&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00642;&#x0062f;&#x00631;&#x00647;&#x00627; 8253 &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;/QALY&#x0060c; &#x00648;&#x00647;&#x0064a; &#x00623;&#x00642;&#x00644; &#x00645;&#x00646; &#x00639;&#x0062a;&#x00628;&#x00629; &#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00639;&#x0062f;&#x00627;&#x0062f; &#x00644;&#x00644;&#x0062f;&#x00641;&#x00639; &#x00627;&#x00644;&#x00628;&#x00627;&#x00644;&#x0063a;&#x00629; &#x00642;&#x0064a;&#x00645;&#x0062a;&#x00647;&#x00627; 23050 &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;/QALY. &#x00623;&#x00638;&#x00647;&#x00631;&#x0062a; &#x0062a;&#x0062d;&#x00644;&#x0064a;&#x00644;&#x00627;&#x0062a; &#x00627;&#x00644;&#x0062d;&#x00633;&#x00627;&#x00633;&#x0064a;&#x00629; &#x00623;&#x0062d;&#x00627;&#x0062f;&#x0064a;&#x00629; &#x00627;&#x00644;&#x00627;&#x0062a;&#x0062c;&#x00627;&#x00647; &#x00648;&#x00627;&#x00644;&#x00627;&#x0062d;&#x0062a;&#x00645;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00623;&#x00646; &#x00627;&#x00644;&#x00646;&#x0062a;&#x00627;&#x00626;&#x0062c; &#x00642;&#x00648;&#x0064a;&#x00629;. &#x00648;&#x00645;&#x00639; &#x00627;&#x00633;&#x0062a;&#x00643;&#x00634;&#x00627;&#x00641; &#x00627;&#x00644;&#x00633;&#x0064a;&#x00646;&#x00627;&#x00631;&#x0064a;&#x00648;&#x00647;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00645;&#x0062e;&#x0062a;&#x00644;&#x00641;&#x00629;&#x0060c; &#x00641;&#x00625;&#x00646; &#x00627;&#x00644;&#x00641;&#x0062d;&#x00635; &#x00643;&#x00644; 3 &#x00633;&#x00646;&#x00648;&#x00627;&#x0062a; &#x0064a;&#x00643;&#x00648;&#x00646; &#x00647;&#x00648; &#x00627;&#x00644;&#x00623;&#x00643;&#x0062b;&#x00631; &#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00645;&#x00646; &#x0062d;&#x0064a;&#x0062b; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629;&#x0060c; &#x00645;&#x00639; &#x00646;&#x00633;&#x00628;&#x00629; &#x00645;&#x0062a;&#x00632;&#x00627;&#x0064a;&#x0062f;&#x00629; &#x00644;&#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x0062a;&#x00628;&#x00644;&#x0063a; 6671 &#x0062f;&#x00648;&#x00644;&#x00627;&#x00631;&#x0064b;&#x00627; &#x00623;&#x00645;&#x00631;&#x0064a;&#x00643;&#x0064a;&#x0064b;&#x00627;/QALY. &#x0062a;&#x00642;&#x00644; &#x00641;&#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00627;&#x00644;&#x00641;&#x0062d;&#x00635; &#x00625;&#x00630;&#x00627; &#x00644;&#x00645; &#x0062a;&#x00642;&#x00645; &#x00643;&#x00644; &#x00627;&#x00644;&#x00646;&#x00633;&#x00627;&#x00621; &#x00627;&#x00644;&#x00644;&#x00648;&#x00627;&#x0062a;&#x0064a; &#x0064a;&#x0062a;&#x00645; &#x0062a;&#x00634;&#x0062e;&#x0064a;&#x00635;&#x00647;&#x00646; &#x00628;&#x00627;&#x00644;&#x00633;&#x00639;&#x0064a; &#x00644;&#x00644;&#x00639;&#x00644;&#x00627;&#x0062c;. &#x00648;&#x00623;&#x0062e;&#x0064a;&#x00631;&#x0064b;&#x00627;&#x0060c; &#x00641;&#x00625;&#x00646; &#x00627;&#x00644;&#x00641;&#x00627;&#x00626;&#x0062f;&#x00629; &#x00627;&#x00644;&#x00627;&#x00642;&#x0062a;&#x00635;&#x00627;&#x0062f;&#x0064a;&#x00629; &#x00644;&#x00641;&#x0062d;&#x00635; &#x00627;&#x00644;&#x00646;&#x00633;&#x00627;&#x00621; &#x00627;&#x00644;&#x00644;&#x00648;&#x00627;&#x0062a;&#x0064a; &#x0062a;&#x0062a;&#x00631;&#x00627;&#x00648;&#x0062d; &#x00623;&#x00639;&#x00645;&#x00627;&#x00631;&#x00647;&#x00646; &#x00628;&#x0064a;&#x00646; 45 &#x00648;69 &#x00639;&#x00627;&#x00645;&#x0064b;&#x00627; &#x00628;&#x00627;&#x00633;&#x0062a;&#x0062e;&#x0062f;&#x00627;&#x00645; &#x00643;&#x00644; &#x00645;&#x00646; &#x00627;&#x00644;&#x00645;&#x00648;&#x0062c;&#x00627;&#x0062a; &#x00641;&#x00648;&#x00642; &#x00627;&#x00644;&#x00635;&#x00648;&#x0062a;&#x0064a;&#x00629; &#x00648;&#x00627;&#x00644;&#x0062a;&#x00635;&#x00648;&#x0064a;&#x00631; &#x00627;&#x00644;&#x00634;&#x00639;&#x00627;&#x00639;&#x0064a; &#x00644;&#x00644;&#x0062b;&#x0062f;&#x0064a;&#x0060c; &#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629;&#x0064b; &#x00628;&#x00627;&#x00644;&#x00641;&#x0062d;&#x00635; &#x00627;&#x00644;&#x00634;&#x00639;&#x00627;&#x00639;&#x0064a; &#x00644;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00648;&#x0062d;&#x0062f;&#x00647;&#x0060c; &#x0063a;&#x0064a;&#x00631; &#x00645;&#x00624;&#x00643;&#x0062f;&#x00629;. </p></sec><sec><title>&#x00627;&#x00644;&#x00627;&#x00633;&#x0062a;&#x00646;&#x0062a;&#x00627;&#x0062c; </title><p>&#x00625;&#x00646; &#x00641;&#x0062d;&#x00635; &#x00633;&#x00631;&#x00637;&#x00627;&#x00646; &#x00627;&#x00644;&#x0062b;&#x0062f;&#x0064a; &#x00641;&#x0064a; &#x00627;&#x00644;&#x0062a;&#x0062c;&#x00645;&#x00639;&#x00627;&#x0062a; &#x00627;&#x00644;&#x00633;&#x00643;&#x00627;&#x00646;&#x0064a;&#x00629; &#x00639;&#x00627;&#x00644;&#x0064a;&#x00629; &#x00627;&#x00644;&#x0062e;&#x00637;&#x00648;&#x00631;&#x00629;&#x0060c; &#x0064a;&#x00639;&#x0062f; &#x00641;&#x00639;&#x00627;&#x00644;&#x00627; &#x00645;&#x00646; &#x0062d;&#x0064a;&#x0062b; &#x00627;&#x00644;&#x0062a;&#x00643;&#x00644;&#x00641;&#x00629; &#x00645;&#x00642;&#x00627;&#x00631;&#x00646;&#x00629; &#x00628;&#x00639;&#x0062f;&#x00645; &#x00625;&#x0062c;&#x00631;&#x00627;&#x00621; &#x00623;&#x0064a; &#x00641;&#x0062d;&#x00635;. </p></sec></trans-abstract><trans-abstract xml:lang="zh"><title>&#x06458;&#x08981;</title><sec><title>&#x076ee;&#x07684;</title><p>&#x04e3a;&#x000a0;2012&#x000a0;&#x05e74;&#x0542f;&#x052a8;&#x07684;&#x04e2d;&#x056fd;&#x057ce;&#x05e02;&#x057fa;&#x04e8e;&#x098ce;&#x09669;&#x07684;&#x04e73;&#x0817a;&#x0764c;&#x07b5b;&#x067e5;&#x09879;&#x076ee;&#x05efa;&#x06a21;&#x08fdb;&#x0884c;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x05206;&#x06790;&#x0ff0c;&#x04e0e;&#x04e0d;&#x07b5b;&#x067e5;&#x07684;&#x060c5;&#x051b5;&#x08fdb;&#x0884c;&#x06bd4;&#x08f83;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x06211;&#x04eec;&#x08fd0;&#x07528;&#x09a6c;&#x05c14;&#x053ef;&#x0592b;&#x06a21;&#x0578b;&#x06765;&#x04f30;&#x08ba1;&#x000a0;40-69&#x000a0;&#x05c81;&#x09ad8;&#x05371;&#x05987;&#x05973;&#x04e73;&#x0817a;&#x0764c;&#x07b5b;&#x067e5;&#x07684;&#x07ec8;&#x08eab;&#x06210;&#x0672c;&#x0548c;&#x06839;&#x0636e;&#x08d28;&#x091cf;&#x08c03;&#x06574;&#x0751f;&#x0547d;&#x05e74;&#x000a0;(QALYs)&#x000a0;&#x07684;&#x07ec8;&#x08eab;&#x06548;&#x05e94;&#x03002;&#x06211;&#x04eec;&#x04ece;&#x05176;&#x04ed6;&#x07814;&#x07a76;&#x04e2d;&#x063a8;&#x05bfc;&#x051fa;&#x06216;&#x091c7;&#x07528;&#x04e86;&#x05404;&#x05e74;&#x09f84;&#x07ec4;&#x053d1;&#x075c5;&#x07387;&#x0548c;&#x08f6c;&#x079fb;&#x06982;&#x07387;&#x06570;&#x0636e;&#x0ff0c;&#x05e76;&#x05047;&#x08bbe;&#x0764c;&#x075c7;&#x04e0d;&#x0540c;&#x05206;&#x0671f;&#x095f4;&#x04e3a;&#x081ea;&#x07136;&#x053d1;&#x05c55;&#x075c5;&#x07a0b;&#x03002;&#x06211;&#x04eec;&#x04ece;&#x04e2d;&#x056fd;&#x000a0;37&#x000a0;&#x05bb6;&#x0533b;&#x09662;&#x07684;&#x04e73;&#x0817a;&#x0764c;&#x060a3;&#x08005;&#x08c03;&#x067e5;&#x04e2d;&#x083b7;&#x05f97;&#x04e86;&#x000a0;2014&#x000a0;&#x05e74;&#x07f8e;&#x05143;&#x000a0;(US$)&#x000a0;&#x07684;&#x07ec8;&#x08eab;&#x076f4;&#x063a5;&#x0548c;&#x095f4;&#x063a5;&#x06cbb;&#x07597;&#x08d39;&#x07528;&#x03002;&#x04e3a;&#x04e86;&#x08ba1;&#x07b97;&#x000a0;QALYs&#x0ff0c;&#x06211;&#x04eec;&#x04ece;&#x06a2a;&#x065ad;&#x09762;&#x060a3;&#x08005;&#x08c03;&#x067e5;&#x04e2d;&#x05f97;&#x051fa;&#x06548;&#x07528;&#x05206;&#x06570;&#x03002;&#x06211;&#x04eec;&#x08bc4;&#x04f30;&#x04e86;&#x04e0d;&#x0540c;&#x060c5;&#x0666f;&#x04e0b;&#x07684;&#x0589e;&#x091cf;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x06bd4;&#x0ff0c;&#x04e0e;&#x0610f;&#x0613f;&#x0652f;&#x04ed8;&#x06700;&#x04f4e;&#x09608;&#x0503c;&#x08fdb;&#x0884c;&#x06bd4;&#x08f83;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x06211;&#x04eec;&#x06bcf;&#x05e74;&#x07b5b;&#x067e5;&#x04e00;&#x06b21;&#x07684;&#x057fa;&#x07ebf;&#x06a21;&#x0578b;&#x05f97;&#x05230;&#x07684;&#x0589e;&#x091cf;&#x06210;&#x0672c;&#x06548;&#x076ca;&#x06bd4;&#x04e3a;&#x000a0;8253&#x000a0;&#x07f8e;&#x05143; /QALY&#x0ff0c;&#x04f4e;&#x04e8e;&#x000a0;23050&#x000a0;&#x07f8e;&#x05143; /QALY&#x000a0;&#x07684;&#x0610f;&#x0613f;&#x0652f;&#x04ed8;&#x06700;&#x04f4e;&#x09608;&#x0503c;&#x03002;&#x05355;&#x056e0;&#x07d20;&#x0548c;&#x06982;&#x07387;&#x0654f;&#x0611f;&#x06027;&#x05206;&#x06790;&#x08868;&#x0660e;&#x07ed3;&#x0679c;&#x053ef;&#x09760;&#x03002;&#x05728;&#x063a2;&#x07d22;&#x04e0d;&#x0540c;&#x060c5;&#x0666f;&#x065f6;&#x0ff0c;&#x06bcf;&#x04e09;&#x05e74;&#x08fdb;&#x0884c;&#x04e00;&#x06b21;&#x07b5b;&#x067e5;&#x06700;&#x05177;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x0ff0c;&#x0589e;&#x091cf;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x06bd4;&#x04e3a;&#x000a0;6671&#x000a0;&#x07f8e;&#x05143; /QALY&#x03002;&#x05982;&#x0679c;&#x05e76;&#x0975e;&#x06240;&#x06709;&#x088ab;&#x08bca;&#x065ad;&#x07684;&#x05973;&#x06027;&#x090fd;&#x05bfb;&#x06c42;&#x06cbb;&#x07597;&#x0ff0c;&#x07b5b;&#x067e5;&#x07684;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x04f1a;&#x0964d;&#x04f4e;&#x03002;&#x06700;&#x0540e;&#x0ff0c;&#x04e0e;&#x05355;&#x072ec;&#x04f7f;&#x07528;&#x04e73;&#x0817a;&#x094bc;&#x09776;&#x000a0;X&#x000a0;&#x07ebf;&#x06444;&#x050cf;&#x06bd4;&#x08f83;&#x0ff0c;&#x0540c;&#x065f6;&#x091c7;&#x07528;&#x08d85;&#x058f0;&#x0548c;&#x04e73;&#x0817a;&#x094bc;&#x09776;&#x000a0;X&#x000a0;&#x07ebf;&#x068c0;&#x067e5;&#x07b5b;&#x067e5;&#x000a0;45-69&#x000a0;&#x05c81;&#x05973;&#x06027;&#x07684;&#x07ecf;&#x06d4e;&#x06548;&#x076ca;&#x05c1a;&#x04e0d;&#x0786e;&#x05b9a;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x04e0e;&#x04e0d;&#x07b5b;&#x067e5;&#x060c5;&#x051b5;&#x076f8;&#x06bd4;&#x0ff0c;&#x09ad8;&#x098ce;&#x09669;&#x04eba;&#x07fa4;&#x07684;&#x04e73;&#x0817a;&#x0764c;&#x07b5b;&#x067e5;&#x05177;&#x06709;&#x06210;&#x0672c;&#x06548;&#x0679c;&#x03002;</p></sec></trans-abstract><trans-abstract xml:lang="ru"><title>&#x00420;&#x00435;&#x00437;&#x0044e;&#x0043c;&#x00435;</title><sec><title>&#x00426;&#x00435;&#x0043b;&#x0044c;</title><p>&#x00421;&#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x00442;&#x0044c; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x00436;&#x00435;&#x0043b;&#x00435;&#x00437;&#x0044b; &#x0043d;&#x00430; &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x00435; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00430; &#x00432; &#x00433;&#x0043e;&#x00440;&#x0043e;&#x00434;&#x00430;&#x00445; &#x0041a;&#x00438;&#x00442;&#x00430;&#x0044f;, &#x0043a;&#x0043e;&#x00442;&#x0043e;&#x00440;&#x00430;&#x0044f; &#x00431;&#x0044b;&#x0043b;&#x00430; &#x00437;&#x00430;&#x0043f;&#x00443;&#x00449;&#x00435;&#x0043d;&#x00430; &#x00432; 2012&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00443;, &#x0043f;&#x00440;&#x00438; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x00438; &#x00441; &#x0043e;&#x00442;&#x00441;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00438;&#x00435;&#x0043c; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x00430;.</p></sec><sec><title>&#x0041c;&#x00435;&#x00442;&#x0043e;&#x00434;&#x0044b;</title><p>&#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x00440;&#x00430;&#x00437;&#x00440;&#x00430;&#x00431;&#x0043e;&#x00442;&#x00430;&#x0043b;&#x00438; &#x0043c;&#x00430;&#x00440;&#x0043a;&#x0043e;&#x00432;&#x00441;&#x0043a;&#x00443;&#x0044e; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c; &#x00434;&#x0043b;&#x0044f; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00435; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00443;&#x00436;&#x00438;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00432; &#x00442;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00438; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432;&#x000a0;(&#x00441; &#x00442;&#x0043e;&#x00447;&#x0043a;&#x00438; &#x00437;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043a;&#x0043e;&#x0043b;&#x00438;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x00430; &#x0043b;&#x00435;&#x00442; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00441; &#x0043f;&#x0043e;&#x0043f;&#x00440;&#x00430;&#x00432;&#x0043a;&#x0043e;&#x00439; &#x0043d;&#x00430; &#x00435;&#x00435; &#x0043a;&#x00430;&#x00447;&#x00435;&#x00441;&#x00442;&#x00432;&#x0043e;&#x000a0;(QALY)) &#x00432;&#x0043d;&#x00435;&#x00434;&#x00440;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00430;&#x0043c;&#x0043c;&#x0044b; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x00436;&#x00435;&#x0043b;&#x00435;&#x00437;&#x0044b; &#x00434;&#x0043b;&#x0044f; &#x00436;&#x00435;&#x0043d;&#x00449;&#x00438;&#x0043d; &#x00441; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x00438;&#x0043c; &#x00440;&#x00438;&#x00441;&#x0043a;&#x0043e;&#x0043c; &#x00432; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00435; 40&#x02013;69&#x000a0;&#x0043b;&#x00435;&#x00442;. &#x00410;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x00432;&#x0044b;&#x00432;&#x00435;&#x0043b;&#x00438; &#x00441;&#x00430;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x0044f;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e; &#x00438;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x00437;&#x00430;&#x00438;&#x0043c;&#x00441;&#x00442;&#x00432;&#x0043e;&#x00432;&#x00430;&#x0043b;&#x00438; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e; &#x00437;&#x00430;&#x00432;&#x00438;&#x00441;&#x00438;&#x0043c;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00447;&#x00430;&#x00441;&#x00442;&#x0043e;&#x00442;&#x0044b; &#x00432;&#x0043e;&#x00437;&#x0043d;&#x00438;&#x0043a;&#x0043d;&#x0043e;&#x00432;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043e;&#x00442; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00430; &#x00438; &#x0043e; &#x00432;&#x00435;&#x00440;&#x0043e;&#x0044f;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043f;&#x00435;&#x00440;&#x00435;&#x00445;&#x0043e;&#x00434;&#x00430;, &#x0043e;&#x00441;&#x0043d;&#x0043e;&#x00432;&#x0044b;&#x00432;&#x00430;&#x0044f;&#x00441;&#x0044c; &#x0043d;&#x00430; &#x00435;&#x00441;&#x00442;&#x00435;&#x00441;&#x00442;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439; &#x00438;&#x00441;&#x00442;&#x0043e;&#x00440;&#x00438;&#x00438; &#x0043f;&#x00440;&#x0043e;&#x00433;&#x00440;&#x00435;&#x00441;&#x00441;&#x00438;&#x00440;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043c;&#x00435;&#x00436;&#x00434;&#x00443; &#x00441;&#x00442;&#x00430;&#x00434;&#x00438;&#x0044f;&#x0043c;&#x00438; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043f;&#x0043e; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x0043c; &#x00434;&#x00440;&#x00443;&#x00433;&#x00438;&#x00445; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439;. &#x00412; &#x00445;&#x0043e;&#x00434;&#x00435; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00439; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x00441; &#x00440;&#x00430;&#x0043a;&#x0043e;&#x0043c; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x00436;&#x00435;&#x0043b;&#x00435;&#x00437;&#x0044b; &#x00432; 37&#x000a0;&#x0043a;&#x00438;&#x00442;&#x00430;&#x00439;&#x00441;&#x0043a;&#x00438;&#x00445; &#x00431;&#x0043e;&#x0043b;&#x0044c;&#x0043d;&#x00438;&#x00446;&#x00430;&#x00445; &#x00431;&#x0044b;&#x0043b;&#x00438; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00435;&#x0043d;&#x0044b; &#x00434;&#x00430;&#x0043d;&#x0043d;&#x0044b;&#x00435; &#x0043e; &#x0043f;&#x00440;&#x0044f;&#x0043c;&#x0044b;&#x00445; &#x00438; &#x0043a;&#x0043e;&#x00441;&#x00432;&#x00435;&#x0043d;&#x0043d;&#x0044b;&#x00445; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442;&#x00430;&#x00445; &#x0043d;&#x00430; &#x0043c;&#x00435;&#x00434;&#x00438;&#x00446;&#x00438;&#x0043d;&#x00441;&#x0043a;&#x0043e;&#x00435; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00443;&#x00436;&#x00438;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00432; &#x00442;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00436;&#x00438;&#x00437;&#x0043d;&#x00438; &#x00432; &#x00434;&#x0043e;&#x0043b;&#x0043b;&#x00430;&#x00440;&#x00430;&#x00445; &#x00421;&#x00428;&#x00410;&#x000a0;(&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410;) &#x0043f;&#x0043e; &#x0043a;&#x00443;&#x00440;&#x00441;&#x00443; 2014&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430;. &#x00427;&#x00442;&#x0043e;&#x00431;&#x0044b; &#x00432;&#x0044b;&#x00447;&#x00438;&#x00441;&#x0043b;&#x00438;&#x00442;&#x0044c; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x00442;&#x00435;&#x0043b;&#x0044c; QALY, &#x00430;&#x00432;&#x00442;&#x0043e;&#x00440;&#x0044b; &#x0043f;&#x0043e;&#x0043b;&#x00443;&#x00447;&#x00438;&#x0043b;&#x00438; &#x00438;&#x0043d;&#x00434;&#x00435;&#x0043a;&#x00441;&#x0044b; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00438; &#x0043e;&#x00431;&#x00449;&#x00435;&#x00433;&#x0043e; &#x00441;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x0044f;&#x0043d;&#x00438;&#x0044f; &#x00437;&#x00434;&#x0043e;&#x00440;&#x0043e;&#x00432;&#x0044c;&#x0044f; &#x00438;&#x00437; &#x0043f;&#x00435;&#x00440;&#x00435;&#x0043a;&#x00440;&#x00435;&#x00441;&#x00442;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x0043f;&#x00430;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432;. &#x00411;&#x0044b;&#x0043b;&#x00430; &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00430; &#x0043e;&#x00446;&#x00435;&#x0043d;&#x0043a;&#x00430; &#x00438;&#x0043d;&#x0043a;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00442;&#x0043d;&#x0044b;&#x00445; &#x0043a;&#x0043e;&#x0044d;&#x00444;&#x00444;&#x00438;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x00432; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x00434;&#x0043b;&#x0044f; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x00446;&#x00435;&#x0043d;&#x00430;&#x00440;&#x00438;&#x00435;&#x00432; &#x00434;&#x0043b;&#x0044f; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044f; &#x00441; &#x0043f;&#x0043e;&#x00440;&#x0043e;&#x00433;&#x0043e;&#x0043c; &#x0043f;&#x0043b;&#x00430;&#x00442;&#x00435;&#x00436;&#x00435;&#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;.</p></sec><sec><title>&#x00420;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b;</title><p>&#x00421;&#x0043e;&#x00437;&#x00434;&#x00430;&#x0043d;&#x0043d;&#x00430;&#x0044f; &#x00430;&#x00432;&#x00442;&#x0043e;&#x00440;&#x00430;&#x0043c;&#x00438; &#x00431;&#x00430;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0044f; &#x0043c;&#x0043e;&#x00434;&#x00435;&#x0043b;&#x0044c; &#x00435;&#x00436;&#x00435;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00433;&#x0043e; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x00430; &#x0043f;&#x00440;&#x00438;&#x00432;&#x00435;&#x0043b;&#x00430; &#x0043a; &#x00443;&#x00432;&#x00435;&#x0043b;&#x00438;&#x00447;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x0043a;&#x0043e;&#x0044d;&#x00444;&#x00444;&#x00438;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x00430; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x00432; &#x00440;&#x00430;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00435; 8253&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410;/QALY, &#x00447;&#x00442;&#x0043e; &#x0043d;&#x00438;&#x00436;&#x00435; &#x0043f;&#x0043e;&#x00440;&#x0043e;&#x00433;&#x00430; &#x0043f;&#x0043b;&#x00430;&#x00442;&#x00435;&#x00436;&#x00435;&#x00441;&#x0043f;&#x0043e;&#x00441;&#x0043e;&#x00431;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00432; &#x00440;&#x00430;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00435; 23&#x000a0;050&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410;/QALY. &#x0041e;&#x00434;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0043e;&#x00440;&#x0043e;&#x0043d;&#x0043d;&#x00438;&#x00439; &#x00438; &#x00432;&#x00435;&#x00440;&#x0043e;&#x0044f;&#x00442;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0043d;&#x0044b;&#x00439; &#x00430;&#x0043d;&#x00430;&#x0043b;&#x00438;&#x00437; &#x00447;&#x00443;&#x00432;&#x00441;&#x00442;&#x00432;&#x00438;&#x00442;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x0043f;&#x0043e;&#x0043a;&#x00430;&#x00437;&#x00430;&#x0043b;, &#x00447;&#x00442;&#x0043e; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0044b; &#x0044f;&#x00432;&#x0043b;&#x0044f;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00430;&#x00434;&#x00435;&#x00436;&#x0043d;&#x0044b;&#x0043c;&#x00438;. &#x00418;&#x00441;&#x00445;&#x0043e;&#x00434;&#x0044f; &#x00438;&#x00437; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x0043e;&#x00432; &#x00438;&#x00441;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00440;&#x00430;&#x00437;&#x0043b;&#x00438;&#x00447;&#x0043d;&#x0044b;&#x00445; &#x00441;&#x00446;&#x00435;&#x0043d;&#x00430;&#x00440;&#x00438;&#x00435;&#x00432;, &#x0043f;&#x00440;&#x0043e;&#x00432;&#x00435;&#x00434;&#x00435;&#x0043d;&#x00438;&#x00435; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00447;&#x00435;&#x00440;&#x00435;&#x00437; &#x0043a;&#x00430;&#x00436;&#x00434;&#x0044b;&#x00435; 3&#x000a0;&#x00433;&#x0043e;&#x00434;&#x00430; &#x0044f;&#x00432;&#x0043b;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00430;&#x00438;&#x00431;&#x0043e;&#x0043b;&#x00435;&#x00435; &#x00440;&#x00435;&#x0043d;&#x00442;&#x00430;&#x00431;&#x00435;&#x0043b;&#x0044c;&#x0043d;&#x0044b;&#x0043c; &#x00441; &#x00438;&#x0043d;&#x0043a;&#x00440;&#x00435;&#x0043c;&#x00435;&#x0043d;&#x00442;&#x0043d;&#x0044b;&#x0043c; &#x0043a;&#x0043e;&#x0044d;&#x00444;&#x00444;&#x00438;&#x00446;&#x00438;&#x00435;&#x0043d;&#x00442;&#x0043e;&#x0043c; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438; &#x00437;&#x00430;&#x00442;&#x00440;&#x00430;&#x00442; &#x00432; &#x00440;&#x00430;&#x00437;&#x0043c;&#x00435;&#x00440;&#x00435; 6671&#x000a0;&#x00434;&#x0043e;&#x0043b;&#x0043b;.&#x000a0;&#x00421;&#x00428;&#x00410;/QALY. &#x0042d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00430;&#x0044f; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00441;&#x0043d;&#x00438;&#x00436;&#x00430;&#x00435;&#x00442;&#x00441;&#x0044f;, &#x00435;&#x00441;&#x0043b;&#x00438; &#x0043d;&#x00435; &#x00432;&#x00441;&#x00435; &#x0043f;&#x00440;&#x0043e;&#x00448;&#x00435;&#x00434;&#x00448;&#x00438;&#x00435; &#x00434;&#x00438;&#x00430;&#x00433;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x00438;&#x0043a;&#x00443; &#x00436;&#x00435;&#x0043d;&#x00449;&#x00438;&#x0043d;&#x0044b; &#x0043e;&#x00431;&#x00440;&#x00430;&#x00449;&#x00430;&#x0044e;&#x00442;&#x00441;&#x0044f; &#x00437;&#x00430; &#x0043b;&#x00435;&#x00447;&#x00435;&#x0043d;&#x00438;&#x00435;&#x0043c;. &#x0041d;&#x00430;&#x0043a;&#x0043e;&#x0043d;&#x00435;&#x00446;, &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00430;&#x0044f; &#x00432;&#x0044b;&#x00433;&#x0043e;&#x00434;&#x0043d;&#x0043e;&#x00441;&#x00442;&#x0044c; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00433;&#x0043e; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x0044f; &#x00436;&#x00435;&#x0043d;&#x00449;&#x00438;&#x0043d; &#x00432; &#x00432;&#x0043e;&#x00437;&#x00440;&#x00430;&#x00441;&#x00442;&#x00435; 45&#x02013;69&#x000a0;&#x0043b;&#x00435;&#x00442; &#x00441; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435;&#x0043c; &#x00438; &#x00443;&#x0043b;&#x0044c;&#x00442;&#x00440;&#x00430;&#x00437;&#x00432;&#x00443;&#x0043a;&#x00430; &#x00438; &#x0043c;&#x00430;&#x0043c;&#x0043c;&#x0043e;&#x00433;&#x00440;&#x00430;&#x00444;&#x00438;&#x00438; &#x0043f;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x00441; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x0043c;&#x00438; &#x0043f;&#x00440;&#x00438; &#x00438;&#x00441;&#x0043f;&#x0043e;&#x0043b;&#x0044c;&#x00437;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00438; &#x00442;&#x0043e;&#x0043b;&#x0044c;&#x0043a;&#x0043e; &#x0043c;&#x00430;&#x0043c;&#x0043c;&#x0043e;&#x00433;&#x00440;&#x00430;&#x00444;&#x00438;&#x00438; &#x0044f;&#x00432;&#x0043b;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0043d;&#x00435;&#x0043e;&#x0043f;&#x00440;&#x00435;&#x00434;&#x00435;&#x0043b;&#x00435;&#x0043d;&#x0043d;&#x0043e;&#x00439;.</p></sec><sec><title>&#x00412;&#x0044b;&#x00432;&#x0043e;&#x00434;</title><p>&#x00421;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x0043e;&#x00432;&#x0043e;&#x00435; &#x0043e;&#x00431;&#x00441;&#x0043b;&#x00435;&#x00434;&#x0043e;&#x00432;&#x00430;&#x0043d;&#x00438;&#x00435; &#x00440;&#x00430;&#x0043a;&#x00430; &#x0043c;&#x0043e;&#x0043b;&#x0043e;&#x00447;&#x0043d;&#x0043e;&#x00439; &#x00436;&#x00435;&#x0043b;&#x00435;&#x00437;&#x0044b; &#x00441;&#x00440;&#x00435;&#x00434;&#x00438; &#x00436;&#x00435;&#x0043d;&#x00449;&#x00438;&#x0043d; &#x00441; &#x00432;&#x0044b;&#x00441;&#x0043e;&#x0043a;&#x00438;&#x0043c; &#x00443;&#x00440;&#x0043e;&#x00432;&#x0043d;&#x00435;&#x0043c; &#x00440;&#x00438;&#x00441;&#x0043a;&#x00430; &#x0044f;&#x00432;&#x0043b;&#x0044f;&#x00435;&#x00442;&#x00441;&#x0044f; &#x0044d;&#x0043a;&#x0043e;&#x0043d;&#x0043e;&#x0043c;&#x00438;&#x00447;&#x00435;&#x00441;&#x0043a;&#x00438; &#x0044d;&#x00444;&#x00444;&#x00435;&#x0043a;&#x00442;&#x00438;&#x00432;&#x0043d;&#x0044b;&#x0043c; &#x0043f;&#x0043e; &#x00441;&#x00440;&#x00430;&#x00432;&#x0043d;&#x00435;&#x0043d;&#x00438;&#x0044e; &#x00441; &#x00440;&#x00435;&#x00437;&#x00443;&#x0043b;&#x0044c;&#x00442;&#x00430;&#x00442;&#x00430;&#x0043c;&#x00438; &#x0043f;&#x00440;&#x00438; &#x0043e;&#x00442;&#x00441;&#x00443;&#x00442;&#x00441;&#x00442;&#x00432;&#x00438;&#x00438; &#x00441;&#x0043a;&#x00440;&#x00438;&#x0043d;&#x00438;&#x0043d;&#x00433;&#x00430;.<bold/></p></sec></trans-abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Breast cancer is the most common cancer among women. Globally, 1.67 million women were diagnosed with breast cancer in 2012, contributing to more than 25% of female cancer incident cases.<xref rid="R1" ref-type="bibr"><sup>1</sup></xref> The incidence of breast cancer among Chinese women is increasing twice as fast as the global rate.<xref rid="R2" ref-type="bibr"><sup>2</sup></xref> In China, breast cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer-related deaths.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref></p><p>Breast cancer is a potentially curable disease if diagnosed and treated at an early stage. The Surveillance, Epidemiology, and End Results Programme reported that women diagnosed with breast cancer at an early stage (Stage I or II) have a better prognosis (5-year survival rate, 85&#x02013;98%) than for advanced breast cancer (5-year survival rate for Stage III or IV, 30&#x02013;70%).<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> The strong argument for earlier diagnosis with respect to patient outcome has resulted in the initiation of breast cancer screening programmes in many countries. The aims of such programmes are the early diagnosis and treatment of cancer patients to improve disease outcomes and to reduce mortality.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>Although population-based mammography has been widely adopted in high-income countries for more than 30&#x000a0;years,<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> it is less cost&#x02013;effective in low- and middle-income countries.<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> Studies in China,<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>&#x02013;</sup><xref rid="R10" ref-type="bibr"><sup>10</sup></xref> Ghana<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> and the Islamic Republic of Iran<xref rid="R12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="R13" ref-type="bibr"><sup>13</sup></xref> have revealed that population-based mammography is not economically attractive. However, a high-risk population-based breast cancer screening programme could contribute to a much higher detection rate<xref rid="R14" ref-type="bibr"><sup>14</sup></xref><sup>&#x02013;</sup><xref rid="R16" ref-type="bibr"><sup>16</sup></xref> and could therefore be good value for money in low- and middle-income countries.</p><p>Experts have recommended ultrasound as an adjunct to mammography among high-risk women.<xref rid="R17" ref-type="bibr"><sup>17</sup></xref><sup>&#x02013;</sup><xref rid="R20" ref-type="bibr"><sup>20</sup></xref> For patients with dense breasts, non-calcified breast cancers are more likely to be missed by mammography;<xref rid="R21" ref-type="bibr"><sup>21</sup></xref> ultrasound permits the detection of small, otherwise occult, breast cancer.<xref rid="R22" ref-type="bibr"><sup>22</sup></xref></p><p>In 2012, the Government of China launched a cancer screening programme in 14 cities to screen common cancers, including breast cancer. Our objective was to provide policy-makers with economic information regarding the cost&#x02013;effectiveness of breast cancer screening for high-risk women. In this paper, we used a Markov model to compare the lifetime effects, costs and cost&#x02013;effectiveness of breast cancer screening, versus no screening, using published data from this programme (<xref ref-type="fig" rid="F1">Fig.&#x000a0;1</xref>).</p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Current risk-based breast cancer screening programme in urban China, launched in 2012</p></caption><graphic xlink:href="BLT.18.207944-F1"/></fig><sec><title>Methods</title><sec><title>Screening strategy</title><p>To measure the individual risk of breast cancer, health professionals invited women aged 40&#x02013;69&#x000a0;years to health facilities and used paper-based questionnaires to collect information on individual breast cancer exposure. The health professionals then used the Harvard Cancer Index online tool, now called Your Disease Risk, to process the collected information.<xref rid="R23" ref-type="bibr"><sup>23</sup></xref><sup>,</sup><xref rid="R24" ref-type="bibr"><sup>24</sup></xref> The tool calculates individual cancer scores, by giving risk scores to exposures, including family history, height, age of first period, age of first birth, number of births, age at menopause, use of oral contraceptives, estrogen replacement, Jewish heritage (i.e. higher prevalence of <italic>BRAC1/2</italic> gene mutations) and exposure to ionizing radiation. A total of 198&#x02009;097 women completed a risk assessment questionnaire during 2012&#x02013;2013; 17&#x02009;104 were identified as being at high risk of developing breast cancer.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><p>The programme working group estimated the population average score based on the prevalence of risk factors among the Chinese population, and adjusted according to China&#x02019;s cancer epidemiology data over 20 years.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> The relative risk was obtained by comparing the individual risk score with the population average. Women with a relative risk of &#x0003e;&#x02009;2 are defined as being at high risk. The programme screens high-risk women aged 40&#x02013;44&#x000a0;years by ultrasound and the women with suspected results are further examined by mammography. Women with a suspicious mammography result are tested by biopsy for diagnostic confirmation. The programme screens high-risk women aged 45&#x02013;69&#x000a0;years by both mammography and ultrasound, and suspected results from either method are confirmed with biopsy.</p><p>For low-risk women, breast cancer is only diagnosed on presentation of symptoms. Breast cancer patients in the screening arm can be diagnosed while still asymptomatic, that is, at an earlier stage of the disease when prognosis is better.</p></sec><sec><title>Modelling strategy</title><p><xref ref-type="boxed-text" rid="B1">Box&#x000a0;1</xref> presents our model assumptions. We adapted a prior natural history Markov model<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> using the TreeAge software (TreeAge software Inc. Williamstown, United States of America), to inform a long-term decision model. Our model predicted the lifetime costs and quality-adjusted life years (QALYs) of screening and no screening for Chinese urban women with no previous history of breast cancer, from age 40&#x000a0;years to death. We used an annual screening frequency as the baseline, and we explored the scenarios of screening every 3 and 5&#x000a0;years.</p><boxed-text id="B1" position="float" orientation="portrait"><label>Box&#x000a0;1</label><caption><title>Model assumptions for estimating cost&#x02013;effectiveness ratios of risk-based breast cancer screening programme in urban China</title></caption><sec><title>Parameters</title><list list-type="bullet" id="L1"><list-item><p>For progression rates between disease stages and relative risk of invasive cancer in ductal carcinoma in situ, we obtained data from other countries and assumed the parameters were applicable to China. We also used disutility score of screening from United Kingdom of Great Britain and Northern Ireland in the baseline analysis. However, we explored the uncertainty in the sensitivity analyses.</p></list-item><list-item><p>We assumed the risk of developing breast cancer among high-risk women was twice as much as the general population, based on the minimum threshold in Harvard Cancer Index (now called Your Disease Risk).</p></list-item></list></sec><sec><title>Model structure</title><list list-type="bullet" id="L2"><list-item><p>We assumed patients at stage I can progress to stage II, stage III and stage IV. All women can die from non-breast cancer causes during disease progression, but only patients at stage IV can die from breast cancer.</p></list-item><list-item><p>We assumed all women with suspicious screening findings either with mammography or ultrasound proceeded to diagnostic biopsy. This follows the protocol of the Cancer Screening Programme in Urban China.</p></list-item><list-item><p>In the base-case analysis, we assumed all breast cancer patients diagnosed by biopsy received treatment. However, because uptake of treatment is uncertain, we explored the scenario where only 70% of detected breast cancers received treatment.</p></list-item></list></sec></boxed-text></sec><sec><title>Natural history</title><p><xref ref-type="fig" rid="F2">Fig.&#x000a0;2</xref> illustrates the various health states and the potential transitions between them.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> Healthy women can transition to ductal carcinoma in situ or stage I cancer, or remain free of cancer. Women with ductal carcinoma in situ are at a higher risk of developing invasive breast cancer (relative risk: 2.02).<xref rid="R4" ref-type="bibr"><sup>4</sup></xref> Patients at stage I can progress to stage II, stage III and stage IV in turn. All women can die from causes other than breast cancer during disease progression, but only patients at stage IV can die from breast cancer. The state progression transition probabilities used in this analysis are from models described in the literature.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref></p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Natural history model for breast cancer progression, China</p></caption><p>Notes: The box represents the process of disease progression. We adapted the model from Wong et al.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="R25" ref-type="bibr"><sup>25</sup></xref> and Tsokos &#x00026; O&#x0011f;uzt&#x000f6;reli.<xref rid="R25" ref-type="bibr"><sup>25</sup></xref></p><graphic xlink:href="BLT.18.207944-F2"/></fig><p>We estimated the probability of symptoms in an unscreened population by calibrating the model as follows. In the non-screening arm, incident cases are only detected on presentation with symptoms; the distribution of incidence cases by stage is therefore a function of the probability of transitions and the probability of symptoms.<xref rid="R26" ref-type="bibr"><sup>26</sup></xref> We adjusted the probability of symptoms until the distribution of cases presented at each stage was similar to the distribution of reported incidence cases.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref><sup>,</sup><xref rid="R27" ref-type="bibr"><sup>27</sup></xref> Our estimates of transition probabilities are provided in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Parameter values for modelling cost&#x02013;effectiveness of risk-based breast cancer screening programme launched in 2012 in urban China</title></caption><table frame="hsides" rules="groups"><col width="104" span="1"/><col width="70" span="1"/><col width="56" span="1"/><col width="63" span="1"/><col width="56" span="1"/><col width="106" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Baseline</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Minimum</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Maximum</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Distribution</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Reference/source</th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1"><bold>Disease state progression transition probabilities</bold></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Age-specific incidence, years</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;40&#x02013;44</td><td valign="top" align="center" rowspan="1" colspan="1">0.0006100</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;45&#x02013;49</td><td valign="top" align="center" rowspan="1" colspan="1">0.0010056</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;50&#x02013;54</td><td valign="top" align="center" rowspan="1" colspan="1">0.0011650</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;55&#x02013;59</td><td valign="top" align="center" rowspan="1" colspan="1">0.0011179</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;60&#x02013;64</td><td valign="top" align="center" rowspan="1" colspan="1">0.0010458</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;65&#x02013;69</td><td valign="top" align="center" rowspan="1" colspan="1">0.0009782</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;70&#x02013;74</td><td valign="top" align="center" rowspan="1" colspan="1">0.0009912</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;75&#x02013;79</td><td valign="top" align="center" rowspan="1" colspan="1">0.0009067</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;80&#x02013;84</td><td valign="top" align="center" rowspan="1" colspan="1">0.0007803</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x02265;&#x02009;85</td><td valign="top" align="center" rowspan="1" colspan="1">0.0006430</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Chinese Cancer Registry Annual Report<xref rid="R3" ref-type="bibr"><sup>3</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ratio of DCIS incidence to invasive breast cancer incidence</td><td valign="top" align="center" rowspan="1" colspan="1">0.12</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Lu et al.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RR of invasive cancer from DICS&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">2.02</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">SEER Program<xref rid="R4" ref-type="bibr"><sup>4</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Progression rate</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage I&#x02013;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">0.06</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tsokos &#x00026; O&#x0011f;uzt&#x000f6;reli<xref rid="R25" ref-type="bibr"><sup>25</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage II&#x02013;Stage III</td><td valign="top" align="center" rowspan="1" colspan="1">0.11</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tsokos &#x00026; O&#x0011f;uzt&#x000f6;reli<xref rid="R25" ref-type="bibr"><sup>25</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III&#x02013;Stage IV</td><td valign="top" align="center" rowspan="1" colspan="1">0.15</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Tsokos &#x00026; O&#x0011f;uzt&#x000f6;reli<xref rid="R25" ref-type="bibr"><sup>25</sup></xref>&#x000a0;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV&#x02013;death</td><td valign="top" align="center" rowspan="1" colspan="1">0.23</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Wong et al.<xref rid="R8" ref-type="bibr"><sup>8</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Stage-specific probability of symptoms</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage I</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Model calibration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">0.014</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Model calibration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III</td><td valign="top" align="center" rowspan="1" colspan="1">0.380</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Model calibration</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV</td><td valign="top" align="center" rowspan="1" colspan="1">0.980</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Model calibration</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Annual fatality rate after treatment</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage I</td><td valign="top" align="center" rowspan="1" colspan="1">0.006</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Ginsberg et al.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">0.042</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Ginsberg et al.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III</td><td valign="top" align="center" rowspan="1" colspan="1">0.093</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Ginsberg et al.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV</td><td valign="top" align="center" rowspan="1" colspan="1">0.275</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="left" rowspan="1" colspan="1">Ginsberg et al.<xref rid="R27" ref-type="bibr"><sup>27</sup></xref></td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1"><bold>Effectiveness of screening</bold></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ultrasound followed by mammography if required<sup>a</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Sensitivity</td><td valign="top" align="center" rowspan="1" colspan="1">0.848</td><td valign="top" align="center" rowspan="1" colspan="1">0.681</td><td valign="top" align="center" rowspan="1" colspan="1">0.949</td><td valign="top" align="center" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">Huang et al.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Specificity</td><td valign="top" align="center" rowspan="1" colspan="1">0.994</td><td valign="top" align="center" rowspan="1" colspan="1">0.990</td><td valign="top" align="center" rowspan="1" colspan="1">0.996</td><td valign="top" align="center" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">Huang et al.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ultrasound and mammography<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Sensitivity</td><td valign="top" align="center" rowspan="1" colspan="1">0.939</td><td valign="top" align="center" rowspan="1" colspan="1">0.798</td><td valign="top" align="center" rowspan="1" colspan="1">0.993</td><td valign="top" align="center" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">Huang et al.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Specificity</td><td valign="top" align="center" rowspan="1" colspan="1">0.980</td><td valign="top" align="center" rowspan="1" colspan="1">0.975</td><td valign="top" align="center" rowspan="1" colspan="1">0.985</td><td valign="top" align="center" rowspan="1" colspan="1">Beta</td><td valign="top" align="left" rowspan="1" colspan="1">Huang et al.<xref rid="R29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Utility scores</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage I</td><td valign="top" align="center" rowspan="1" colspan="1">0.79</td><td valign="top" align="center" rowspan="1" colspan="1">0.77</td><td valign="top" align="center" rowspan="1" colspan="1">0.80</td><td valign="top" align="center" rowspan="1" colspan="1">Log-normal</td><td valign="top" align="left" rowspan="1" colspan="1">Shi et al.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">0.79</td><td valign="top" align="center" rowspan="1" colspan="1">0.78</td><td valign="top" align="center" rowspan="1" colspan="1">0.80</td><td valign="top" align="center" rowspan="1" colspan="1">Log-normal</td><td valign="top" align="left" rowspan="1" colspan="1">Shi et al.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.77<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.76<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.79<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Log-normal<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Shi et al.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.69<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.65<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.72<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Log-normal<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Shi et al.<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Disutility from false-positive<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.11<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.34<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Log-normal<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Peasgood et al.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"><bold>Costs, US$</bold><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1">&#x000a0;<hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Questionnaire<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gamma<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Cancer Screening Programme in Urban China<xref rid="R32" ref-type="bibr"><sup>32</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Screening<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">85.5<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59.8<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">111.1<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gamma<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Cancer Screening Programme in Urban China<xref rid="R32" ref-type="bibr"><sup>32</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Biopsy<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45.6<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31.0<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">59.3<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gamma<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Cancer Screening Programme in Urban China<xref rid="R32" ref-type="bibr"><sup>32</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Treatment costs<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DCIS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2435<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1705<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3166<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">Gamma<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Li et al.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref><hr/></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage I</td><td valign="top" align="center" rowspan="1" colspan="1">10&#x02009;067</td><td valign="top" align="center" rowspan="1" colspan="1">7047</td><td valign="top" align="center" rowspan="1" colspan="1">13&#x02009;087</td><td valign="top" align="center" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">Liao et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage II</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;068</td><td valign="top" align="center" rowspan="1" colspan="1">7748</td><td valign="top" align="center" rowspan="1" colspan="1">14&#x02009;388</td><td valign="top" align="center" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">Liao et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage III</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;867</td><td valign="top" align="center" rowspan="1" colspan="1">9007</td><td valign="top" align="center" rowspan="1" colspan="1">16&#x02009;727</td><td valign="top" align="center" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">Liao et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Stage IV</td><td valign="top" align="center" rowspan="1" colspan="1">17&#x02009;766</td><td valign="top" align="center" rowspan="1" colspan="1">12&#x02009;436</td><td valign="top" align="center" rowspan="1" colspan="1">23&#x02009;096</td><td valign="top" align="center" rowspan="1" colspan="1">Gamma</td><td valign="top" align="left" rowspan="1" colspan="1">Liao et al.<xref rid="R34" ref-type="bibr"><sup>34</sup></xref></td></tr></tbody></table><table-wrap-foot><p>DCIS: ductal carcinoma in situ; US$: United States dollars.</p><p><sup>a</sup> For women aged 40&#x02013;44 years.</p><p><sup>b</sup> For women aged 45&#x02013;69&#x000a0;years.</p></table-wrap-foot></table-wrap><p>We assumed that all suspected cases proceeded to biopsy and that all diagnosed cases received treatment at baseline. We also explored a scenario of only 70% treatment uptake.</p></sec><sec><title>Epidemiological and clinical data</title><p>We obtained the age-specific invasive breast cancer incidences from the 2012 Chinese Cancer Registry Annual Report.<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> Since ductal carcinoma in situ incidence is not recorded locally, we estimated the proportion of ductal carcinoma in situ among all breast cancer incidence cases from a Chinese study of 3838 patients.<xref rid="R28" ref-type="bibr"><sup>28</sup></xref> We calculated age-specific mortalities from other causes by subtracting age-specific breast cancer mortality rates<xref rid="R35" ref-type="bibr"><sup>35</sup></xref> from the corresponding age-specific all-cause mortality rates.<xref rid="R36" ref-type="bibr"><sup>36</sup></xref></p></sec><sec><title>Costs</title><p>Data describing the costs of questionnaire, screening (whether ultrasound followed by mammography if required or ultrasound plus mammography, depending on age) and biopsy were available from the screening programme.<xref rid="R32" ref-type="bibr"><sup>32</sup></xref> We also obtained the treatment costs by stage from the study by the programme working group;<xref rid="R34" ref-type="bibr"><sup>34</sup></xref> such treatment cost data were estimated from 2746 invasive breast cancer patients from 37 hospitals across 13 provinces in China, comprising direct medical costs, direct non-medical costs and indirect costs. We used the disposable income per capita of Chinese urban residents (22.5 United States dollars (US$) per day)<xref rid="R37" ref-type="bibr"><sup>37</sup></xref> and productivity loss days to calculate the indirect costs. The Chinese screening programme did not report treatment costs for women with ductal carcinoma in situ, so we estimated these costs from a study of 211 Sichuan Cancer Hospital patients.<xref rid="R33" ref-type="bibr"><sup>33</sup></xref> All costs are presented at 2014 values. We used the purchasing power parity conversion factor to convert cost values to US$, with US$&#x000a0;1 equal to 3.51 Chinese yuan.<xref rid="R38" ref-type="bibr"><sup>38</sup></xref></p></sec><sec><title>Effectiveness of screening</title><p>We used the sensitivity (probability of positive diagnosis if diseased) and specificity (probability of negative diagnosis if not diseased) values from an earlier study<xref rid="R29" ref-type="bibr"><sup>29</sup></xref> that enrolled 3062 Chinese women (average age, 45&#x000a0;years) at risk of breast cancer. 11 screening modalities were compared, which are different combinations of clinical breast examination, mammography and ultrasound.<bold><italic/></bold>We varied the estimates in the sensitivity analyses in case of any variation in diagnostic performance due to the age of the screened population.</p></sec><sec><title>QALYs</title><p>QALY is a measurement that reflects both length of life and health-related quality of life. It is calculated as the product of the utility score of a particular state of health, defined as a dimensionless number between 1 (perfect health) and 0 (death), and the number of years lived. We identified the utility scores for patients at stage I, II, III and IV from a cross-sectional survey conducted as part of the screening programme,<xref rid="R30" ref-type="bibr"><sup>30</sup></xref> in which breast cancer patients across 13 Chinese provinces completed EuroQol five-dimensional questionnaires.</p><p>False-positive results could be argued to undermine quality of life due to psychological distress incurred;<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> a systematic review estimated a utility decrement (disutility) of 11&#x02013;34% for false-positive results.<xref rid="R31" ref-type="bibr"><sup>31</sup></xref> We estimated a loss of 25% at baseline<xref rid="R40" ref-type="bibr"><sup>40</sup></xref> and explored the uncertainty in the sensitivity analysis.</p></sec><sec><title>Analysis</title><p>In agreement with the China Guidelines for Pharmacoeconomic Evaluations,<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> we conducted the analysis from a societal perspective. In agreement with these guidelines,<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> we discounted future costs and future benefits at 3%. We estimated the lifetime costs of screening and its effects in terms of QALY. We calculated the incremental cost&#x02013;effectiveness ratios, defined as the difference in cost divided by the change in QALY. The willingness-to-pay threshold was estimated to be three times the gross domestic product (GDP) per capita in China in 2014 (US$&#x000a0;7683).<xref rid="R42" ref-type="bibr"><sup>42</sup></xref> An incremental cost&#x02013;effectiveness ratio of less than US$&#x000a0;23&#x02009;050/QALY<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> is therefore an indication that the risk-based breast cancer screening for urban Chinese women aged 40&#x02013;69&#x000a0;years, compared with no screening, is cost&#x02013;effective.</p><p>To explore the effect of parameter uncertainty, we conducted one-way and probabilistic sensitivity analyses. In the one-way sensitivity analysis, we used the minimum and maximum estimates for effectiveness of screening, utility scores and costs. We varied each parameter individually to assess its impact on overall results. In the probabilistic sensitivity analysis, we varied all variables simultaneously to further explore model uncertainty. The input variables were specified as distributions: costs have a gamma distribution; QALY values follow a log-normal distribution; and sensitivity and specificity of screening follow a beta distribution as suggested in the literature.<xref rid="R43" ref-type="bibr"><sup>43</sup></xref> By varying input parameters over their respective distributions, we obtained 1000 estimates of incremental costs and incremental effects. We then plotted the cost&#x02013;effectiveness acceptability curves to show the proportion of simulations for which the intervention was cost&#x02013;effective at different willingness-to-pay thresholds.</p><p>Other scenarios explored included: (i)&#x000a0;the impact of screening every 3&#x000a0;years or every 5&#x000a0;years, compared with no screening; (ii)&#x000a0;screening every year, but only 70% of the detected cases having access to breast cancer treatment; and (iii) screening women aged 45&#x02013;69&#x000a0;years every 1, 3 and 5&#x000a0;years via mammography and ultrasound, compared with mammography alone (maintaining the original screening strategy for women aged 40&#x02013;44&#x000a0;years).</p></sec></sec></sec><sec sec-type="results"><title>Results</title><p>Our model estimated 43 incident cases of breast cancer per 1000 women over a lifetime; 21 were detected via screening and 22 on presentation with symptoms. <xref rid="T2" ref-type="table">Table&#x000a0;2</xref> reports the discounted lifetime costs, QALYs and incremental cost&#x02013;effectiveness ratios. Overall, the risk-based breast cancer screening yielded higher QALYs compared with no screening (23.0129 QALYs versus 22.9843 QALYs), but was more expensive than no screening (US$&#x000a0;335.43 versus US$&#x000a0;99.68). The baseline discounted incremental cost&#x02013;effectiveness ratio was US$&#x000a0;8253/QALY, well below the threshold of US$&#x000a0;23&#x02009;050/QALY, indicating that the risk-based breast cancer screening programme is cost&#x02013;effective.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Modelled cost&#x02013;effectiveness ratios of risk-based breast cancer screening programme in urban China, 2014</title></caption><table frame="hsides" rules="groups"><col width="117" span="1"/><col width="63" span="1"/><col width="49" span="1"/><col width="70" span="1"/><col width="56" span="1"/><col width="109" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Comparators</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Lifetime costs per case (US$)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">QALY</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Incremental costs (US$)</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">Difference in QALY</th><th valign="top" align="center" scope="col" rowspan="1" colspan="1">ICER (95% CI)<sup>a</sup></th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"><bold>Baseline analysis</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No screening</td><td valign="top" align="center" rowspan="1" colspan="1">99.68</td><td valign="top" align="center" rowspan="1" colspan="1">22.9843</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual screening</td><td valign="top" align="center" rowspan="1" colspan="1">335.43</td><td valign="top" align="center" rowspan="1" colspan="1">23.0129</td><td valign="top" align="center" rowspan="1" colspan="1">235.76</td><td valign="top" align="center" rowspan="1" colspan="1">0.0286</td><td valign="top" align="center" rowspan="1" colspan="1">8&#x000a0;253 (6&#x02009;170 to 11&#x02009;483)</td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1"><bold>Screening programme variations versus no screening</bold></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Screening every 3&#x000a0;years</td><td valign="top" align="center" rowspan="1" colspan="1">184.67</td><td valign="top" align="center" rowspan="1" colspan="1">22.9971</td><td valign="top" align="center" rowspan="1" colspan="1">84.99</td><td valign="top" align="center" rowspan="1" colspan="1">0.0127</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;671 (5&#x02009;019 to 9&#x02009;048)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Screening every 5&#x000a0;years</td><td valign="top" align="center" rowspan="1" colspan="1">152.09</td><td valign="top" align="center" rowspan="1" colspan="1">22.9919</td><td valign="top" align="center" rowspan="1" colspan="1">52.41</td><td valign="top" align="center" rowspan="1" colspan="1">0.0076</td><td valign="top" align="center" rowspan="1" colspan="1">6&#x000a0;917 (5&#x02009;157 to 9&#x02009;416)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual screening, but only 70% of detected cases treated</td><td valign="top" align="center" rowspan="1" colspan="1">324.17</td><td valign="top" align="center" rowspan="1" colspan="1">23.0043</td><td valign="top" align="center" rowspan="1" colspan="1">224.49</td><td valign="top" align="center" rowspan="1" colspan="1">0.0200</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;223 (8&#x02009;137 to 17&#x02009;127)</td></tr><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1"><bold>Mammography only versus mammography and ultrasound<sup>b</sup></bold></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Annual screening</td><td valign="top" align="center" rowspan="1" colspan="1">306.41</td><td valign="top" align="center" rowspan="1" colspan="1">23.0115</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;29.02</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.0014</td><td valign="top" align="center" rowspan="1" colspan="1">21&#x02009;246 (&#x02212;172&#x02009;049 to 168&#x02009;866)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Screening every 3&#x000a0;years</td><td valign="top" align="center" rowspan="1" colspan="1">172.94</td><td valign="top" align="center" rowspan="1" colspan="1">22.9960</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;11.73</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.0011</td><td valign="top" align="center" rowspan="1" colspan="1">11&#x02009;000 (&#x02212;73&#x02009;330 to 99&#x02009;983)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Screening every 5&#x000a0;years</td><td valign="top" align="center" rowspan="1" colspan="1">145.37</td><td valign="top" align="center" rowspan="1" colspan="1">22.9912</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;6.72</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.0007</td><td valign="top" align="center" rowspan="1" colspan="1">9&#x000a0;366 (&#x02212;114&#x02009;804 to 98&#x02009;149)</td></tr></tbody></table><table-wrap-foot><p>CI: confidence interval; ICER: incremental cost&#x02013;effectiveness ratio; RR: relative risk; QALY: quality-adjusted life year; US$ United States dollars.</p><p><sup>a</sup> Discounted at 3%.</p><p><sup>b</sup> For women aged 45&#x02013;69 years. Screening regime for women aged 40&#x02013;44&#x000a0;years remains unchanged.</p><p>Note: Some inconsistency arise in some value due to rounding.</p></table-wrap-foot></table-wrap><p>The one-way sensitivity analysis (<xref ref-type="fig" rid="F3">Fig.&#x000a0;3</xref>) indicates that the costs, utility scores and effectiveness of screening have little individual influence on the cost&#x02013;effectiveness of the programme. We found the incremental cost&#x02013;effectiveness ratios to be lower than the threshold at both the upper and lower limits of these variables. The results of the probabilistic sensitivity analysis (<xref ref-type="fig" rid="F4">Fig.&#x000a0;4</xref>) show that, at the threshold of US$&#x000a0;23&#x02009;050/QALY, nearly 100% of the simulations indicate that the risk-based breast cancer screening programme is cost&#x02013;effective compared with no screening.</p><fig id="F3" fig-type="figure" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>One-way sensitivity analysis of modelled cost&#x02013;effectiveness of risk-based breast cancer screening programme, urban China, 2014</p></caption><p>ICER: incremental cost&#x02013;effectiveness ratio; QALY: quality-adjusted life year; US$: United States dollars.</p><p>Notes: The width of the bars represents the range of ICER when each parameter was varied individually. The vertical dashed line represents incremental cost&#x02013;effectiveness ratio of US$ 8253/QALY.</p><graphic xlink:href="BLT.18.207944-F3"/></fig><fig id="F4" fig-type="figure" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Probabilistic sensitivity analysis of modelled cost&#x02013;effectiveness of risk-based breast cancer screening programme, urban China, 2014</p></caption><p>QALY: quality-adjusted life year; US$: United States dollars.</p><p>Note: The vertical dashed line represents incremental cost&#x02013;effectiveness ratio of US$ 8253/QALY.</p><graphic xlink:href="BLT.18.207944-F4"/></fig><p>In the scenario analysis (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>), screening every 3&#x000a0;years and every 5&#x000a0;years achieves an incremental cost&#x02013;effectiveness ratio of US$&#x000a0;6671/QALY and US$&#x000a0;6917/QALY, respectively. A scenario of annual screening, but where only 70% of detected cases are treated, yields a higher incremental cost&#x02013;effectiveness ratio of&#x000a0;US$&#x000a0;11&#x02009;223/QALY, which is still lower than the threshold. We also found the scenario of both mammography and ultrasound for women aged 45&#x02013;69&#x000a0;years, compared with mammography alone, to be cost&#x02013;effective. However, in the probabilistic sensitivity analysis, the confidence intervals of the incremental cost&#x02013;effectiveness ratios are very wide: an indication of considerable uncertainty.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>The results indicate that compared with no screening, the risk-based breast cancer screening programme is cost&#x02013;effective. The results prove to be robust in the sensitivity analyses when we varied the estimates for effectiveness of screening, utility scores and costs.</p><p>Our finding that high-risk population-based breast screening is cost&#x02013;effective has implications for breast cancer control in other low- and middle-income countries. Previous studies have reported that population-based mammography screening is not economically attractive in countries, such as the Islamic Republic of Iran and Ghana, with incremental cost&#x02013;effectiveness ratios of US$&#x000a0;389&#x02009;184/QALY<xref rid="R12" ref-type="bibr"><sup>12</sup></xref> and US$&#x000a0;12&#x02009;908/QALY,<xref rid="R11" ref-type="bibr"><sup>11</sup></xref> respectively. The Chinese screening programme is more likely to be cost&#x02013;effective than other general population-based screening programmes, since the detection rate in the Chinese programme is higher (16%)<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> than in general screening programmes (e.g. 3% in the United States of America and 6% in New Zealand).<xref rid="R15" ref-type="bibr"><sup>15</sup></xref><sup>,</sup><xref rid="R16" ref-type="bibr"><sup>16</sup></xref> This finding is consistent with the study comparing risk-based breast cancer screening strategies with general programmes, reporting that risk-based strategies result in greater health benefits for a given cost.<xref rid="R44" ref-type="bibr"><sup>44</sup></xref></p><p>For high-risk women aged 45&#x02013;69&#x000a0;years, our scenario analysis shows that the benefits of ultrasound in addition to mammography are considerably uncertain. The wide confidence intervals, indicating uncertainty in the incremental cost&#x02013;effectiveness ratios, do not appear to justify the increased costs. A potential alternative to the current screening strategy could therefore be mammography screening alone for high-risk women aged 45&#x02013;69&#x000a0;years, instead of both ultrasound and mammography.</p><p>Screening every 3&#x000a0;years is the most cost&#x02013;effective frequency among alternatives. Compared with screening every year, screening every 3&#x000a0;years decreases the total costs significantly, but does not change the effects significantly. The results vindicate the 3-year screening interval for breast cancer in some countries, such as the United Kingdom of Great Britain and Northern Ireland.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>Our study explored the impact of access to treatment on the overall results, suggesting that the screening programme is less cost&#x02013;effective if not all detected cases go on to receive treatment. In China, patients need to pay on average 34% of total medical costs;<xref rid="R45" ref-type="bibr"><sup>45</sup></xref> this can limit access to medical treatment for some women who have been diagnosed with breast cancer. Some women may also decide not to seek medical treatment if they are not experiencing any pain or do not feel ill;<xref rid="R46" ref-type="bibr"><sup>46</sup></xref> such delays in the onset of treatment can however lead to a poorer prognosis,<xref rid="R46" ref-type="bibr"><sup>46</sup></xref> reducing the cost&#x02013;effectiveness of a screening programme.</p><p>As with the previous models,<xref rid="R8" ref-type="bibr"><sup>8</sup></xref> we adopted the Markov approach in our modelling. While costs and quality of life are provided in the publications by the Chinese screening programme,<xref rid="R30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="R32" ref-type="bibr"><sup>32</sup></xref><sup>,</sup><xref rid="R34" ref-type="bibr"><sup>34</sup></xref> no long-term follow-up data are available. We therefore used a mathematical model from age 40 years to death to reflect the differences in costs and effects. We also adopted a prior natural history model, meaning that women free of breast cancer first transition to ductal carcinoma in situ or stage I, followed by the remaining stages in sequence; in contrast, another study<xref rid="R47" ref-type="bibr"><sup>47</sup></xref> used a model in which it is possible to progress from being free of breast cancer to stage IV. In addition, we calibrated our model to estimate the probability of symptoms by cancer stage, using the distribution of incidence cases reported in the Chinese Cancer Registry Annual Report 2012<xref rid="R3" ref-type="bibr"><sup>3</sup></xref> in an unscreened population.</p><p>Further, we incorporated the decrements in health-related quality of life from false-positive screening results into our model. In this analysis, we used a loss of 25% at baseline and explored the uncertainty (11&#x02013;34%). However, the utility loss from false&#x02013;positive results<xref rid="R39" ref-type="bibr"><sup>39</sup></xref> remains controversial. Although some argue that pathologically elevated levels of distress and anxiety are not apparent,<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> the relatively small number of studies means that the long-term effects of false-positive breast cancer screening are still unknown.<xref rid="R48" ref-type="bibr"><sup>48</sup></xref> In this analysis we used estimates from studies based in the United Kingdom of Great Britain and Northern Ireland,<xref rid="R31" ref-type="bibr"><sup>31</sup></xref><sup>,</sup><xref rid="R40" ref-type="bibr"><sup>40</sup></xref> which might bias the cost&#x02013;effectiveness results of the Chinese screening programme. However, we explored the uncertainty and the results proved to be robust through the sensitivity analyses.</p><p>Limitations of our study also include the assumption of high-risk women having a cancer risk index twice that of other women;<xref rid="R23" ref-type="bibr"><sup>23</sup></xref> the real relative risk among high-risk women in urban China is still unknown. Further, the costs of questionnaires and clinical screening in this study are derived from the cost accounting of the screening programme; other implementation costs such as the identification of eligible women, the administration of risk questionnaires and other ancillary costs were not included. This may lead to an underestimation of costs and subsequently the cost&#x02013;effectiveness. For progression rates between stages and the relative risk of invasive cancer from ductal carcinoma in situ, we used data from other countries and assumed the parameters were applicable to China. These factors require careful consideration and further research is required to reduce uncertainty.</p><p>We used three times the Chinese gross domestic product (GDP) per capita as the willingness-to-pay threshold in our cost&#x02013;effectiveness analysis. Although GDP-based thresholds are commonly cited,<xref rid="R41" ref-type="bibr"><sup>41</sup></xref> they have been critized.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref> Even if estimated accurately, GDP-based cost&#x02013;effectiveness ratios, or other estimates of willingness to pay, do not provide information on affordability, budget impact or the feasibly of implementation. Although cost&#x02013;effectiveness ratios are informative in assessing value for money, willingness-to-pay thresholds should therefore not be used alone as a decisions rule for priority setting. Local policy context must also be considered.<xref rid="R49" ref-type="bibr"><sup>49</sup></xref></p><p>In conclusion, our analysis provides economic evidence for the cost&#x02013;effectiveness of risk-based breast cancer screening in urban China.</p></sec></body><back><fn-group><title>Funding:</title><fn fn-type="supported-by"><p>This study has been funded by the National Natural Science Foundation of China (grant no. 71273016 and 71673004). LS has been a master student in School of Public Health, Peking University and received a scholarship from China Medical Board to do research at the London School of Hygiene and Tropical Medicine.</p></fn></fn-group><fn-group><title>Competing interests:</title><fn fn-type="financial-disclosure"><p>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><string-name><surname>Ferlay</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Soerjomataram</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Dikshit</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Eser</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mathers</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Rebelo</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.</article-title>
<source>Int J Cancer</source>. <year>2015</year>
<month>3</month>
<day>1</day>;<volume>136</volume>(<issue>5</issue>):<fpage>E359</fpage>&#x02013;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.29210</pub-id><pub-id pub-id-type="pmid">25220842</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><string-name><surname>Fan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Strasser-Weippl</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>St Louis</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Finkelstein</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Yu</surname>
<given-names>KD</given-names></string-name>, <etal>et al.</etal>
<article-title>Breast cancer in China.</article-title>
<source>Lancet Oncol</source>. <year>2014</year>
<month>6</month>;<volume>15</volume>(<issue>7</issue>):<fpage>e279</fpage>&#x02013;<lpage>89</lpage>. <pub-id pub-id-type="doi">10.1016/S1470-2045(13)70567-9</pub-id><pub-id pub-id-type="pmid">24872111</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="book">National Cancer Center, Disease Prevention and Control Bureau Ministry of Health. Chinese cancer registry annual report, 2012 ed. Beijing: Military Medical Sciences Press; 2012.</mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="web">SEER Program. Division of Cancer Prevention and Control, Surveillance Program, Cancer Statistics Branched [internet]. Bethesda: National Cancer Institute; 2002. Available from: <ext-link ext-link-type="uri" xlink:href="https://seer.cancer.gov/">https://seer.cancer.gov/</ext-link> [cited 2018 Jun 25].</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="web">Breast Cancer Screening Programs in 26 ICSN Countries, 2012: Organization, Policies, and Program Reach. Rockville: National Cancer Institute; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="https://healthcaredelivery.cancer.gov/icsn/breast/screening.html">https://healthcaredelivery.cancer.gov/icsn/breast/screening.html</ext-link> [cited 19 June 2018].</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><string-name><surname>Shen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Duan</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women.</article-title>
<source>Br J Cancer</source>. <year>2015</year>;<volume>112</volume>(<issue>6</issue>):<fpage>998</fpage>&#x02013;<lpage>1004</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2015.33</pub-id><pub-id pub-id-type="pmid">25668012</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><string-name><surname>Lauby-Secretan</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Scoccianti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Loomis</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Benbrahim-Tallaa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Bouvard</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bianchini</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>; <collab>International Agency for Research on Cancer Handbook Working Group</collab>. <article-title>Breast-cancer screening&#x02013;viewpoint of the IARC Working Group.</article-title>
<source>N Engl J Med</source>. <year>2015</year>
<month>6</month>
<day>11</day>;<volume>372</volume>(<issue>24</issue>):<fpage>2353</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMsr1504363</pub-id><pub-id pub-id-type="pmid">26039523</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><string-name><surname>Wong</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Kuntz</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Cowling</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Leung</surname>
<given-names>GM</given-names></string-name>. <article-title>Cost effectiveness of mammography screening for Chinese women.</article-title>
<source>Cancer</source>. <year>2007</year>
<month>8</month>
<day>15</day>;<volume>110</volume>(<issue>4</issue>):<fpage>885</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.22848</pub-id><pub-id pub-id-type="pmid">17607668</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><string-name><surname>Wong</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Kuntz</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Cowling</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Leung</surname>
<given-names>GM</given-names></string-name>. <article-title>Cost-effectiveness analysis of mammography screening in Hong Kong Chinese using state-transition Markov modelling.</article-title>
<source>Hong Kong Med J</source>. <year>2010</year>
<month>6</month>;<volume>16</volume>
<issue>Suppl 3</issue>:<fpage>38</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">20601733</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><string-name><surname>Wong</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Tsang</surname>
<given-names>JW</given-names></string-name>, <string-name><surname>Cowling</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Leung</surname>
<given-names>GM</given-names></string-name>. <article-title>Optimizing resource allocation for breast cancer prevention and care among Hong Kong Chinese women.</article-title>
<source>Cancer</source>. <year>2012</year>
<month>9</month>
<day>15</day>;<volume>118</volume>(<issue>18</issue>):<fpage>4394</fpage>&#x02013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.27448</pub-id><pub-id pub-id-type="pmid">22359352</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><string-name><surname>Zelle</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Nyarko</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Bosu</surname>
<given-names>WK</given-names></string-name>, <string-name><surname>Aikins</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ni&#x000eb;ns</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Lauer</surname>
<given-names>JA</given-names></string-name>, <etal>et al.</etal>
<article-title>Costs, effects and cost-effectiveness of breast cancer control in Ghana.</article-title>
<source>Trop Med Int Health</source>. <year>2012</year>
<month>8</month>;<volume>17</volume>(<issue>8</issue>):<fpage>1031</fpage>&#x02013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-3156.2012.03021.x</pub-id><pub-id pub-id-type="pmid">22809238</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><string-name><surname>Haghighat</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Akbari</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Yavari</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Javanbakht</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ghaffari</surname>
<given-names>S</given-names></string-name>. <article-title>Cost-effectiveness of three rounds of mammography breast cancer screening in Iranian women.</article-title>
<source>Iran J Cancer Prev</source>. <year>2016</year>;<volume>9</volume>(<issue>1</issue>):<fpage>e5443</fpage>.<pub-id pub-id-type="pmid">27366315</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><string-name><surname>Barfar</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Rashidian</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hosseini</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nosratnejad</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Barooti</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zendehdel</surname>
<given-names>K</given-names></string-name>. <article-title>Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women.</article-title>
<source>Arch Iran Med</source>. <year>2014</year>
<month>4</month>;<volume>17</volume>(<issue>4</issue>):<fpage>241</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">24724599</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><string-name><surname>Mi</surname>
<given-names>ZH</given-names></string-name>, <string-name><surname>Ren</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>HZ</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal>
<article-title>[Analysis for the breast cancer screening among urban populations in China, 2012-2013]</article-title>. <source>Zhonghua Yu Fang Yi Xue Za Zhi</source>. <year>2016</year>
<month>10</month>
<day>6</day>;<volume>50</volume>(<issue>10</issue>):<fpage>887</fpage>&#x02013;<lpage>92</lpage>. <comment>[Chinese.]</comment><pub-id pub-id-type="pmid">27686767</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Miglioretti</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Metz</surname>
<given-names>CE</given-names></string-name>, <string-name><surname>Schmidt</surname>
<given-names>RA</given-names></string-name>. <article-title>Breast cancer detection rate: designing imaging trials to demonstrate improvements.</article-title>
<source>Radiology</source>. <year>2007</year>
<month>5</month>;<volume>243</volume>(<issue>2</issue>):<fpage>360</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1148/radiol.2432060253</pub-id><pub-id pub-id-type="pmid">17456866</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><string-name><surname>Richardson</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Graham</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Brown</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Smale</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cox</surname>
<given-names>B</given-names></string-name>. <article-title>Breast cancer detection rates, and standardised detection ratios for prevalence screening in the New Zealand breast cancer screening programme.</article-title>
<source>J Med Screen</source>. <year>2004</year>;<volume>11</volume>(<issue>2</issue>):<fpage>65</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1258/096914104774061038</pub-id><pub-id pub-id-type="pmid">15153320</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><string-name><surname>Smith</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Saslow</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Sawyer</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Burke</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Costanza</surname>
<given-names>ME</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>WP</given-names>
<suffix>3rd</suffix></string-name>, <etal>et al.; </etal><collab>American Cancer Society Breast Cancer Advisory Group</collab>. <article-title>American Cancer Society guidelines for breast cancer screening: update 2003.</article-title>
<source>CA Cancer J Clin</source>. <year>2003</year>
<season>May-Jun</season>;<volume>53</volume>(<issue>3</issue>):<fpage>141</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.3322/canjclin.53.3.141</pub-id><pub-id pub-id-type="pmid">12809408</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><string-name><surname>Albert</surname>
<given-names>US</given-names></string-name>, <string-name><surname>Altland</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Duda</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Engel</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Geraedts</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Heywang-K&#x000f6;brunner</surname>
<given-names>S</given-names></string-name>, <etal>et al.</etal>
<article-title>2008 update of the guideline: early detection of breast cancer in Germany.</article-title>
<source>J Cancer Res Clin Oncol</source>. <year>2009</year>
<month>3</month>;<volume>135</volume>(<issue>3</issue>):<fpage>339</fpage>&#x02013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1007/s00432-008-0450-y</pub-id><pub-id pub-id-type="pmid">18661152</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="book"><source>Management of breast cancer in women.</source>
<publisher-loc>Edinburgh</publisher-loc>: <publisher-name>SIGN Scottish Intercollegiate Guideline Network</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="book"><collab>NCCN National Comprehensive Cancer Network</collab>. <source>Breast cancer screening and diagnosis guidelines.</source>
<publisher-loc>Fort Washington</publisher-loc>:<publisher-name> NCCN Clinical Practice Guidelines in Oncology</publisher-name>; <year>2007</year>.</mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><string-name><surname>Gartlehner</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Thaler</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Chapman</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kaminski-Hartenthaler</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Berzaczy</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Van Noord</surname>
<given-names>MG</given-names></string-name>, <etal>et al.</etal>
<article-title>Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2013</year>;(<issue>4</issue>):<fpage>CD009632</fpage>.<pub-id pub-id-type="pmid">23633376</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><string-name><surname>Nothacker</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Duda</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hahn</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Warm</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Degenhardt</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Madjar</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review.</article-title>
<source>BMC Cancer</source>. <year>2009</year>;<volume>9</volume>(<issue>1</issue>):<fpage>335</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-9-335</pub-id><pub-id pub-id-type="pmid">19765317</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><string-name><surname>Colditz</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Atwood</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Emmons</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Monson</surname>
<given-names>RR</given-names></string-name>, <string-name><surname>Willett</surname>
<given-names>WC</given-names></string-name>, <string-name><surname>Trichopoulos</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal>
<article-title>Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. </article-title><source>Cancer Causes Control</source>. <year>2000</year>
<month>7</month>;<volume>11</volume>(<issue>6</issue>):<fpage>477</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1023/A:1008984432272</pub-id><pub-id pub-id-type="pmid">10880030</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><string-name><surname>Voelker</surname>
<given-names>R</given-names></string-name>. <article-title>Quick uptakes: online risk assessment expands.</article-title>
<source>JAMA</source>. <year>2000</year>
<month>7</month>
<day>26</day>;<volume>284</volume>(<issue>4</issue>):<fpage>430</fpage>.<pub-id pub-id-type="pmid">10904490</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><string-name><surname>Tsokos</surname>
<given-names>CP</given-names></string-name>, <string-name><surname>O&#x0011f;uzt&#x000f6;reli</surname>
<given-names>MN</given-names></string-name>. <article-title>A probabilistic model for breast cancer survival data.</article-title>
<source>Comput Math Appl</source>. <year>1987</year>;<volume>14</volume>(<issue>9&#x02013;12</issue>):<fpage>835</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/0898-1221(87)90232-X</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><string-name><surname>Myers</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>McCrory</surname>
<given-names>DC</given-names></string-name>, <string-name><surname>Nanda</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Bastian</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Matchar</surname>
<given-names>DB</given-names></string-name>. <article-title>Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis.</article-title>
<source>Am J Epidemiol</source>. <year>2000</year>
<month>6</month>
<day>15</day>;<volume>151</volume>(<issue>12</issue>):<fpage>1158</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a010166</pub-id><pub-id pub-id-type="pmid">10905528</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><string-name><surname>Ginsberg</surname>
<given-names>GM</given-names></string-name>, <string-name><surname>Lauer</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Zelle</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baeten</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Baltussen</surname>
<given-names>R</given-names></string-name>. <article-title>Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study.</article-title>
<source>BMJ</source>. <year>2012</year>;<volume>344</volume>:<fpage>e614</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.e614</pub-id><pub-id pub-id-type="pmid">22389347</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><string-name><surname>Lu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Shao</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Wen</surname>
<given-names>C</given-names></string-name>. <article-title>[Analysis of treatment cost of breast cancer patients with different clinical stages]</article-title>. <source>Zhongguo Weisheng Ziyuan</source>. <year>2011</year>;<volume>14</volume>(<issue>3</issue>):<fpage>154</fpage>&#x02013;<lpage>7</lpage>. <comment>[Chinese.]</comment></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kang</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>JY</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>LH</given-names></string-name>, <etal>et al.</etal>
<article-title>Combined performance of physical examination, mammography, and ultrasonography for breast cancer screening among Chinese women: a follow-up study.</article-title>
<source>Curr Oncol</source>. <year>2012</year>
<month>7</month>;<volume>19</volume>
<issue>Suppl 2</issue>:<fpage>eS22</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.3747/co.19.1137</pub-id><pub-id pub-id-type="pmid">22876165</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><string-name><surname>Shi</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Liang</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal>
<article-title>Quality-of-life and health utility scores for common cancers in China: a multicentre cross-sectional survey.</article-title>
<source>Lancet</source>. <year>2016</year>;<volume>388</volume>:<fpage>S29</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(16)31956-0</pub-id></mixed-citation></ref><ref id="R31"><label>31</label><mixed-citation publication-type="book"><string-name><surname>Peasgood</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ward</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Brazier</surname>
<given-names>J</given-names></string-name>. <source>A review and analysis of health state utility values in breast cancer: SCHARR.</source>
<publisher-loc>Sheffield</publisher-loc>: <publisher-name>University of Sheffield</publisher-name>; <year>2010</year>.</mixed-citation></ref><ref id="R32"><label>32</label><mixed-citation publication-type="book"><source>Beijing Municipal Health and Family Planning Commission&#x02019;s notification on distribution of the 2014 national public health special project for chronic disease prevention and control.</source>
<publisher-loc>Beijing</publisher-loc>: <publisher-name>Beijing Municipal Commission of Health and Family Planning</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>JY</given-names></string-name>. <article-title>[Standard treatment cost of female breast cancer at different TNM stages]</article-title>. <source>Zhonghua Zhong Liu Za Zhi</source>. <year>2013</year>
<month>12</month>;<volume>35</volume>(<issue>12</issue>):<fpage>946</fpage>&#x02013;<lpage>50</lpage>. <comment>[Chinese.]</comment><pub-id pub-id-type="pmid">24506967</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><string-name><surname>Liao</surname>
<given-names>XZ</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>JF</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>HY</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>LW</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>XY</given-names></string-name>, <etal>et al.</etal>; <collab>Health Economic Evaluation Working Group, Cancer Screening Program in Urban China (CanSPUC)</collab>. <article-title>Medical and non-medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross-sectional study.</article-title>
<source>Asia Pac J Clin Oncol</source>. <year>2018</year>
<month>6</month>;<volume>14</volume>(<issue>3</issue>):<fpage>167</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1111/ajco.12703</pub-id><pub-id pub-id-type="pmid">28670694</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="web">China Public Health Statistical Yearbook. 2010. Beijing: National Health and Family Planning Commission of the People&#x02019;s Republic of China; 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://en.nhfpc.gov.cn">http://en.nhfpc.gov.cn</ext-link> [cited 2018 Jun 25].</mixed-citation></ref><ref id="R36"><label>36</label><mixed-citation publication-type="web">National Bureau of Statistics. Tabulation on the 2010 population census of the people&#x02019;s republic of China, 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm">http://www.stats.gov.cn/english/Statisticaldata/CensusData/rkpc2010/indexch.htm</ext-link> [cited 19 June 2018].</mixed-citation></ref><ref id="R37"><label>37</label><mixed-citation publication-type="web">Per capita disposable income of urban households in China from 2007 to 2017 (in yuan) [internet]. Hamburg: STATISTICA; 2017. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.statista.com/statistics/289186/china-per-capita-disposable-income-urban-households/">https://www.statista.com/statistics/289186/china-per-capita-disposable-income-urban-households/</ext-link> [cited 2018 Jun 22].</mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="web">PPP conversion factor, GDP (LCU per international $) [internet]. Washington, DC: The World Bank; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/indicator/PA.NUS.PPP">http://data.worldbank.org/indicator/PA.NUS.PPP</ext-link> [cited 2018 Jun 25].</mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><string-name><surname>G&#x000f8;tzsche</surname>
<given-names>PC</given-names></string-name>, <string-name><surname>J&#x000f8;rgensen</surname>
<given-names>KJ</given-names></string-name>. <article-title>Screening for breast cancer with mammography.</article-title>
<source>Cochrane Database Syst Rev</source>. <year>2013</year>;(<issue>6</issue>):<fpage>CD001877</fpage>.<pub-id pub-id-type="pmid">23737396</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><string-name><surname>Raftery</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Chorozoglou</surname>
<given-names>M</given-names></string-name>. <article-title>Possible net harms of breast cancer screening: updated modelling of Forrest report.</article-title>
<source>BMJ</source>. <year>2011</year>
<month>12</month>
<day>8</day>;<volume>343</volume>:<fpage>d7627</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.d7627</pub-id><pub-id pub-id-type="pmid">22155336</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="book"><source>[China guidelines for pharmacoeconomic evaluations]</source>. <publisher-loc>Beijing</publisher-loc>: <publisher-name>China Center for Health Economics Research</publisher-name>; <year>2016</year>
<comment>[Chinese.]</comment></mixed-citation></ref><ref id="R42"><label>42</label><mixed-citation publication-type="web">GDP per capita (current US$) [internet].Washington, DC: The World Bank; 2016. Available from: <ext-link ext-link-type="uri" xlink:href="http://data.worldbank.org/indicator/NY.GDP.PCAP.CD">http://data.worldbank.org/indicator/NY.GDP.PCAP.CD</ext-link> [cited 2018 Jun 25].</mixed-citation></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><string-name><surname>Briggs</surname>
<given-names>A</given-names></string-name>. <article-title>Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty.</article-title>
<source>Value Health</source>. <year>2005</year>
<season>Jan-Feb</season>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1111/j.1524-4733.2005.08101.x</pub-id><pub-id pub-id-type="pmid">15841888</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><string-name><surname>Vilaprinyo</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Forn&#x000e9;</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Carles</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sala</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pla</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Castells</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal>; <collab>Interval Cancer (INCA) Study Group</collab>. <article-title>Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer.</article-title>
<source>PLoS One</source>. <year>2014</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e86858</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0086858</pub-id><pub-id pub-id-type="pmid">24498285</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="web">Global health expenditure database [internet]. Geneva: World Health Organization; 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://apps.who.int/nha/database">http://apps.who.int/nha/database</ext-link> [cited 2018 Jun 22].</mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><string-name><surname>Garcia</surname>
<given-names>HB</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>PY</given-names></string-name>. <article-title>Knowledge about cancer and use of health care services among Hispanic and Asian-American older adults.</article-title>
<source>J Psychosoc Oncol</source>. <year>1989</year>;<volume>6</volume>(<issue>3-4</issue>):<fpage>157</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1300/J077v06n03_11</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><string-name><surname>Wong</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Kuntz</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Cowling</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Lam</surname>
<given-names>CL</given-names></string-name>, <string-name><surname>Leung</surname>
<given-names>GM</given-names></string-name>. <article-title>Cost effectiveness of mammography screening for Chinese women.</article-title>
<source>Cancer</source>. <year>2007</year>
<month>8</month>
<day>15</day>;<volume>110</volume>(<issue>4</issue>):<fpage>885</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.22848</pub-id><pub-id pub-id-type="pmid">17607668</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><string-name><surname>Brewer</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Salz</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Lillie</surname>
<given-names>SE</given-names></string-name>. <article-title>Systematic review: the long-term effects of false-positive mammograms.</article-title>
<source>Ann Intern Med</source>. <year>2007</year>
<month>4</month>
<day>3</day>;<volume>146</volume>(<issue>7</issue>):<fpage>502</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-146-7-200704030-00006</pub-id><pub-id pub-id-type="pmid">17404352</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><string-name><surname>Bertram</surname>
<given-names>MY</given-names></string-name>, <string-name><surname>Lauer</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>De Joncheere</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Edejer</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Hutubessy</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kieny</surname>
<given-names>MP</given-names></string-name>, <etal>et al.</etal>
<article-title>Cost-effectiveness thresholds: pros and cons.</article-title>
<source>Bull World Health Organ</source>. <year>2016</year>
<month>12</month>
<day>1</day>;<volume>94</volume>(<issue>12</issue>):<fpage>925</fpage>&#x02013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2471/BLT.15.164418</pub-id><pub-id pub-id-type="pmid">27994285</pub-id></mixed-citation></ref></ref-list></back></article>